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Phase two metabolic genes are primary targets for a range of nuclear receptors within 
the body.  These include but are not limited to PXR, FXR, and LXR all of which 
create a complex network of crosstalk pathways between members to establish and 
maintain efficient sensing, resulting ultimately in the elimination of potentially 
harmful endogenous/exogenous toxin. The Vitamin D Receptor (VDR) is a member 
of the nuclear receptor super family and is activated in a ligand dependent manner.  
VDRs neoclassical potential has been well established in transactivation roles within 
phase one and three metabolic gene families such as Cytochrome P450 members, and 
ATP-binding Cassette transporters, however very little is understood of VDRs 
prospective role within phase two metabolism.   
Uridine 5’-diphospho-glucuronosyltransferase (UGT) are one of the major phase two 
metabolic gene families and are highly expressed within the liver, lower intestinal and 
kidney to name a few.  The extra hepatic activity of UGT members’ may now have an 
influence on the body’s pharmacokinetic potential (Nakamura et al., 2008b). tract 
chief among which is UGT1A1.  UGT1A1 is involved in the glucuronidation of 
endogenous and exogenous compounds including steroids, chemotherapeutics such as 
Irinotecan used to treat colon cancer and small cell lung cancer, and bile acids, 
generating more hydrophilic metabolites.  In many cancerous disease states including 
liver and biliary, UGT1A expression is down regulated leading to impaired metabolic 
functioning (Strassburg et al., 1997).  This is also relevant in genetic diseases such as 
Gilbert’s Syndrome and Crigler-Najjar Syndrome.   
VDRs role in regulating UGTs was assessed through qRT-PCR analysis, exposing 
LS180 (colon), and HepG2 (liver) respectively to a range of VDR agonists, using 
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known regulators of UGT as positive controls.  Further investigation was undertaken 
to identify the VDRE within the promoter of UGT1A1 and assessing its functionality 
as a nuclear receptor motif through site directed mutagenesis.  It was noted that the 
isolated VDRE also is the binding motif for PXR therefore the loss of this motif 
resulted in the loss of both VDR and PXR as a regulator of UGT1A1.   
To conclude we have shown through luciferase activity that VDR has the potential to 
positively regulate UGT1A1 to a comparable level of already known nuclear receptor 
regulator PXR.  This could lead to the potential regulation of UGT1A1 through diet 
supplementation of vitamin D using both natural and synthetic sources, in a range of 
inflammatory and genetic disease states allowing for a potential therapeutic to be 
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1.1 Vitamin D 
Vitamin D is a fat-soluble hormone that is synthesized through the skin when exposed 
to UVB radiation generated from sunlight exposure (Kulie et al., 2009).  The pre 
hormone, once synthesized in the skin requires two metabolic transformations.  The 
active hormone produced is 1,25(OH)2D3, binds to the cognate Vitamin D Receptor 
(VDR) modulating the genetic expression of a number of biological networks.   The 
established ‘classical’ role of vitamin D encompasses maintenance of calcium and 
phosphate homeostasis to ensure bone mineralization.  In addition, vitamin D has 
been shown to play a fundamental roles in cellular differentiation, immune function, 
and apoptotic pathways (Aranow, 2011).  Vitamin D deficiency has been well studied 
and documented and as such has been linked with a number of disease phenotypes 
with the most established in a clinical context being the risk of developing rickets in 
children or osteomalacia in adults (Sahay and Sahay, 2012). Furthermore vitamin D 
deficiency has been associated with an increased risk of developing certain cancers, 
auto immune diseases, type one and two diabetes, hypertension and heart disease (Ke 
et al., 2015). 
  
 17 
1.2 Vitamin D biosynthesis, calcium/phosphate homeostasis 
7-Dehydrocholesterol is a cholesterol precursor and undergoes an ordered sequence of 
metabolic alterations to form the active metabolite 1,25(OH)2D3, also known as 
calcitriol (Wacker and Holick, 2013).  It is the presence of this precursor in human 
skin that eventually enables the generation of 1,25(OH)2D3 from exposure to 
ultraviolet in sunlight, initially generating an intermediary metabolite, cholecaliferol, 
before further down stream metabolic activities within the liver and kidney to 




















Figure 1.1: Overview detailing the biosynthesis of the active metabolite of vitamin 
D through UVB radiation and subsequent metabolic turn over.   
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Photochemical synthesis of the intermediary metabolite occurs within the cutaneous 
layers of the skin were 7-dehydrocholesterol is converted to cholecaliferol on 
exposure to UVB radiation.  It is this metabolite that is found in the diet and can be 
used to fortify a range of foodstuffs ensuring adequate levels are present to reduce the 
risks of developing vitamin D deficiencies.  Almost 100% of circulating vitamin D 
metabolites are bound to a vitamin D binding protein (DBP) which can act as a 
reservoir of vitamin D that under the right conditions can release ligand to stimulate 
VDR mediated biological responses.   DBP works in this way to avoid unwanted 
toxicity of vitamin D accumulation through controlling its access to target tissues.  
 
Once cholecaliferol has been formed it is hydroxylated in the liver at carbon 25 to 
form 25(OH)D3 or Calcidiol.   This process of hydroxylation is carried out through the 
actions of the cytochrome P450 super family of enzymes that include CYP27A1.  
25(OH)D3 is the major metabolite associated with studies of vitamin D status (Holick, 
2003). The action of 1-α hydroxylase located within the kidney is primarily controlled 
through the endocrine actions of parathyroid hormone (PTH), calcium and phosphate 
levels, and fibroblast growth factor 23 (FGF23).  Biologically active 1,25(OH)2D3 
generates a feedback loop inhibiting the production and secretion of PTH (Khundmiri 
et al., 2016).  FGF23 on the other hand inhibits renal transformation of vitamin D 
through inhibition of the 1-α hydroxylase pathway while simultaneously increasing 
the expression and activity of 24-α hydroxylase resulting in the generation of 
24,25(OH)2D, an inactive form of vitamin D.  
The importance of vitamin D to bone health has been well studied since the 1930’s 
with the maintenance of calcium and phosphate homeostasis to ensure adequate bone 
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matrix formation remaining the fundamental and classical function of vitamin D.  The 
trans-cellular uptake of calcium is highly controlled through VDR medicated activity 
orchestrating the expression of calcium uptake genes such as members of the transient 
receptor potential cation channel sub family; TRPV6 which highly expressed within 
the duodenum of the intestinal tract and enables the entry of calcium into enterocytes.  
1.3 Vitamin D deficiency, defined    
The definition of vitamin D deficiency is a topic of ongoing debate.  The World 
Health Organisation (WHO) defines vitamin D insufficiency as serum levels lower 
than 20ng/ml.  The National Institute for Health and Care Excellence (NICE) 
guidelines state that levels lower than 10ng/ml qualify as deficient.   
The diagnosis of low vitamin D levels can be achieved through assessing the levels of 
circulating 25-hydroxyvitamin D within the blood.  Although there are many 
differences of opinion of what constitutes vitamin D deficiency vs. insufficiency most 
authorities agree that levels lower than 20ng/ml (50nmol/L) is suboptimal for skeletal 
human health.  
In 2016 the European Food Safety Authority (EFSA) derived dietary reference values 
for vitamin D.  It is now considered that the serum 25(OH)D concentration, reflecting 
both the dietary and cutaneous derived sources to be a valid biomarkers of vitamin D 
status children and adults. It is therefore considered that a serum concentration of 
50nmol/L is a suitable target through the acquisition of 15μg/day based on meta 
regression analysis studies.   
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1.4 Extra-renal production of 1,25D3 
1,25(OH)2D3 can be synthesized outside those organs classically associated with its 
production and biotransformation.  In these instances the active vitamin D metabolite 
is being synthesized in a PTH independent fashion and can only elicit an affect on the 
tissue that synthesized it.  In other words the 1,25(OH)2D3 synthesis outside of the 
kidneys does not circulate away from its site of production.  PTH- independent extra-
renal synthesis of 1,25(OH)2D3 from 25(OH)D has been witnessed in activated 
macrophages in the lung and lymph nodes due to the expression of 1- α hydroxylase 
activity (Zhang et al., 2012). Extra renal production of 1,25(OH)2D3  as in 
keratinocytes and macrophages is under different control, being stimulated primarily 
by cytokines such as tumour necrosis factor alpha (TNFa) and interferon gamma 
(IFNg) (Gil et al., 2018). 
  However the most well recognized extra renal expression of 1- α hydroxylase 
remains that of patients suffering from granulomatous, (inherited primary immune 
deficiency disease (PID)).  Through the massive localization of immune cells, 
physiologically active 1,25(OH)2D3 can spill into the peripheral circulation.  
Therefore it is this evidence bolstered with the 1- α hydroxylase expression in other 
extra renal sites that has prompted the idea that auto and paracrine synthesis of 
1,25(OH)2D3 can contribute to normal physiological functioning, with a key role 
appearing to be within innate and acquired immune responses (Hewison et al., 2007).        
1.5 Pathophysiology of vitamin D deficiency  
1,25(OH)2D3 opens calcium channels within the gut, stimulates the formation of 
calcium binding proteins in intestinal cells facilitating the uptake of calcium and 
phosphate from the gut.  The action of bone mineralization is a passive process, 
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occurring once sufficient calcium and vitamin D is available.  In a vitamin D deficient 
state, a less than optimal amount of vitamin D is available; as a result less calcium 
will be available for bone mineralization.  This results in a cascade of endocrine 
reactions, ultimately leading to an increase in parathyroid hormone (PTH) production, 
stimulating the hydroxylation of 25(OH)D by the kidney in an effort to re establish 
adequate circulating levels of active vitamin D, however the increase in serum PTH 
results in increase bone turn over and eventual bone loss as a result due to the 
hypocalcaemic state in the body’s attempts to re establish a normocalcemic 
environment.  If chronic vitamin D deficiency occurs bone loss can be increased 
leading to the onset and development of related disease states with an increasing 
chance of bone fracture predominantly witnessed in the hip, vertebrae and forearms 










Figure 1.2: The pathophysiological pathways from vitamin D deficiency to 
osteoporosis, osteomalacia, resulting in falls and fractures, adapted from (Lips and 
van Schoor, 2011). 
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1.6 Vitamin D & rickets   
Rickets is most commonly witnessed in children and like osteomalacia develops due 
to a chronic deficiency of active vitamin D in conjunction with hypocalcaemia or 
hypophosphatemia.  Both rickets and osteomalacia share many similarities yet they 
have distinct differences; in rickets there is deficient mineralization at the growth 
plate whereas osteomalacia has a deficiency of bone mineralization within the matrix 
structure. The pathogenesis of rickets occurs within the growth plate of the bone, were 
there is a build up of osteoid, usually mineralized through calcium salts, however in 
osteomalacia the mineralization defect leads to a build up of osteoid below the growth 
plate resulting in bone weakness and eventual bowing in the major load bearing bones 
(Ozono, 2016).  A number of population-based studies have been carried out to assess 
the prevalence of vitamin D insufficiency amongst children in Great Britain. A 
number of these studies have concluded that the diagnosis vitamin D deficiency has 
markedly increased over the last decade in the United Kingdom (Basatemur et al., 
2017). The associated higher risk of Vitamin D insufficiency) VDI was witnessed in 
those children who exercised less outside, were overweight and watched more TV, 
this also highlighting potential modifiable risk factors that could be used to reduce the 






1.7 Vitamin D, beyond bone health 
Vitamin D has long been known and understood to be a requirement for overall health 
that is highly evidenced through many diseases phenotypes associated with a 
reduction in vitamin D status and activity.  An appreciation for how vitamin D 
achieves its range of biological effects requires an understanding of the molecular 
mechanisms employed by VDR. (Christakos et al., 2013).  Vitamin D has been the 
focus of a number of epidemiological studies that have made a direct correlation with 
a number of cancerous states including prostate and breast cancer (Moukayed and 
Grant, 2013).  Those areas with increased natural sunlight exposure have a reduced 
incidence rate of prostate and breast cancers, due the overall increase in vitamin D 
production within these populations (Zhalehjoo et al., 2016).  Furthermore VDR has 
been associated with other esoteric effects such as immune response, cellular 
differentiation (Eyles et al., 2005).  Many tissues have been found to express VDR to 
varying degrees.  It is this broad affinity of expression across many tissue types that 
have led much research into the additional roles VDR may play outside that of bone 
health and structure. 
1.7.1 Immune response   
Vitamin D is now regarded by many as an immune modulator due to its defined 
molecular effects within the innate and adaptive immune responses.  A number of 
studies have highlighted how impaired vitamin D status has important effects on the 
immune response to infection and inflammation associated activities, linked with 
autoimmune disorders (Agmon-Levin et al., 2013).    
VDR expression has been witnessed in many cells within the immune system 
including monocytes, dendritic cells and B/T-lymphocytes.  The interaction between 
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vitamin D and immune cells indicates that these cells are no longer constrained to the 
effects mediated through the endocrine actions.  A subclass of the T cell super family 
known as helper T cells, express VDR lending more credence to VDR’s influence 
within the immune system (Cantorna et al., 2015).  These cells are involved in antigen 
presentation as well as the production of many factors involved in overall immune 
response including interleukins two and five (Il-2, IL-5), and tumour necrosis factor 
(TNF) allowing for the potential influences that VDR could have spread across many 
pathways within immune regulation.  Vitamin D has been observed to reduce the 
amount of interleukins produced by the helper T cells controlling cellular proliferation 
(Cantorna et al., 2015).  Furthermore vitamin D has been seen to be involved in a 
number of autoimmune disorders, in such conditions as rheumatoid arthritis and 
inflammatory bowel disease. Those individuals who have reduced vitamin D status 
have significantly more aggressive phenotypes (Kempinska-Podhorodecka et al., 
2017).   
Macrophages, another key member of the immune response have been deemed an 
extra renal source of the enzymatic activity of 1-alpha-hydroxylase, giving these cells 
the ability to produce biologically active 1,25(OH)2D3 acting upon T and/or B cells 
impacting immune regulation. For example studies of innate immunity have shown 
intracrine induction of antimicrobial events through vitamin D as a pivotal 
requirement for macrophages response to infection (Hewison, 2010).  Renal enzyme 
activity is predominantly under the homeostatic control of PTH and 1,25(OH)2D3 
itself whereas immune cell production of the active metabolite seems to be beyond the 












It has become clear in recent years that many tissues involved in the autocrine 
systems have the ability to synthesis 1,25(OH)2D3.  This ability to synthesis 
1,25(OH)2D3 serves as a key link in signaling pathways that connects extracellular 
stimuli to downstream genomic responses.  When target tissues and cells are exposed 
to signals requiring genomic action to produce a protein in response, the presence of 
intracellular vitamin D facilitates the efficient transcriptional responses. Without the 
presence of vitamin D the ability of many cells to respond to pathologic and 
physiologic signals is effected.  An example of which is the ductal epithelium of 
breast tissue that requires vitamin D to respond to cyclic variations in estrogen and 
progesterone (Zinser et al., 2002).  Further to this many of the epithelial structure in 
Figure 1.3: (A) Indicates the scheme by which vitamin D exerts its effect on the 
body BEFORE 1-alpha-hydroylase was recognized outside of the kidney. (B) 
Shows the incorporation of extra renal hydroxylation (Heaney, 2008). 
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the body use vitamin D to signal down stream transcriptional events that regulate 
cellular differentiation, proliferation and apoptosis (Heaney, 2008).     
Vitamin D plays an essential function in the innate antimicrobial immune response 
leading to a cascade of downstream antimicrobial mechanisms to defend against 
invading pathogens.  A major pathway in humans is the activation of Toll-like 
receptor (TLR) superfamily.   TLR 1 and 2 binding leads to increased downstream 
binding of VDR mediated through vitamin D dependent induction of antimicrobial 
proteins. This culminates in giving 1,25(OH)2D3 the ability to bind VDR forming the 
associated complex of 1,25D3:VDR: Retinoid X Receptor (from this point referred to 
as RXR) which is a heterodimeric partner of many nuclear receptor family members 
including VDR, allowing for the direct association and subsequent binding of DNA 
response elements within target genes such genes as cathelocidin and beta defensin 4 
(Liu et al., 2006b), (Lykouras et al., 2016).  Interleukins have also been shown to play 
important roles within innate antimicrobial response.  Interleukins (IL) are secreted 
proteins known as cytokines that are signaling molecules produced by CD4 
lymphocytes, macrophages, monocytes and endothelial cells.  IL-14 and 15 are of 
particular interest as these cytokines are able to induce the expression of CYP27B1 
allowing the facilitated conversion of 25-hydroxy-vitamin D3 to its biologically 
active state leading to VDR activation of genes such as cathelicidin (Krutzik et al., 
2008). 
Cathelicidin is an antimicrobial peptide found within the lysosomes of macrophages 
and plays a critical role in the defense against bacterial infections.  Cathelicidin 
peptides were originally discovered in neutrophils but have since been found to be 
expressed in a number of different cell types within the innate immune system (Liu et 
al., 2006a).   
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1.8 Vitamin D, a 21st century perspective  
The capacity of vitamin D to impact upon biological processes that extend beyond 
bone health has motivated much research as to its molecular function and interactions 
with other signaling pathways.  Vitamin D is known to effect the regulation of a 
number of signaling pathways including those involved in insulin production (Alvarez 
and Ashraf, 2010), tumour necrosis factor alpha (TNF-alpha) synthesis and cytokine 
expression (Yu-Ting et al., 2010). Furthermore having the ability to regulate 
processes within the cell cycle, apoptosis, actin remodeling and cell adhesion lends 
credence to the integral role vitamin D may play in overall genome stability 
(Berridge, 2015).  It has been hypothesized that vitamin D has anti aging effects 
having the ability to influence the length of telomeres within cells and has been linked 
lower associated risks of developing a number of chronic disease states (Mazidi et al., 
2017). 
Supporting this are the functional interactions that have been defined between vitamin 
D, VDR and alpha Klotho hereafter referred to as Klotho and FGF23 as well as Nrf2 
pathways. 
 Fibroblast growth factor 23 or FGF23 was initially characterized in 2000 and is a 
member of the fibroblast family of genes which are responsible for phosphate and 
vitamin D metabolism and is readily secreted by osteocytes in response to elevated 
levels of 1,25(OH)2D3.  It has been shown to have a direct influence on vitamin D 
levels within the body through feedback mechanisms controlling the regulation of 
renal 1-alpha-hydroxylase, ultimately effecting calcium absorption within the body 
(Christakos et al., 2015).  FGF23 was originally defined as a phosphaturic bone-
derived hormone, however recent advances have shed light on major functions of 
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FGF23 and Klotho signaling in renal tissue, heart, and bone.  It is now apparent that 
FGF23 is understood to be a pleiotropic endocrine and auto-/paracrine factor not only 
involved in phosphate homeostasis, but also in calcium and sodium metabolism and 
homeostasis.  Furthermore additional associations have been made with regards bone 
mineralization as well as in the development of cardiac hypertrophy.  
 Klotho is a transmembrane protein and discovered originally as an anti aging factor 
(Kuro-o et al., 1997), as mutations in the mouse counterpart lead to syndromes 
resembling ‘aging’. 
Klotho functions as a co receptor with FGF23 involved in phosphate homeostasis.  
Further pleiotropic functions have been attributed to Klotho including protection 
against oxidative stress, inhibition of apoptosis, and promotion of vascularisation and 
angiogenesis (Lim et al., 2015).    
Age related phenotypes associated with Klotho deficient mice are characterised by 
age related phenotypes that include the onset of osteomalacia, and ectopic 
calcifications (Haussler et al., 2012).  FGF23 has become in recent years identified as 
a novel phosphate regulator within the body.  1,25(OH)2D3 has been shown to induce 
the release of FGF23 from oesteocytic cells as well as working in close harmony with 
klotho acting as a co-receptor, which remains a bona fide longevity factor primary 
expressed in the distal tubule of the renal structures. 
The major activity of FGF23 are to repress the expression of CYP27B1 when in an 
hyperphosphataemic state, ultimately creating a negative feedback loop repressing 
vitamin D bioactivation in the kidney.  This process is further heightened through the 
activation of CYP24A1 to further lower the levels of biologically active 1,25(OH)2D3 
through increased degradation. The relationship between vitamin D/FGF23 and   
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Klotho remains an area of intense research.  Further speculation suggests that the 
relationship between the bone and kidney through the unique interactions may be 
crucial for healthful aging by reducing the risk of developing chronic disease states.  
Bone remains the major source of FGF23, and the kidney is the major site of control 
of both klotho and 1,25D, ultimately benefiting from mineral metabolism, but perhaps 
expanding into the immune system and vasculature (Haussler et al., 2016). 
 
1.9 Nuclear receptors, a molecular overview 
The nuclear hormone receptor super family include receptors associated with the 
following lipophilic molecules; steroid hormones, thyroid, retinoids, and vitamin D 
(Aranda and Pascual, 2001b).  Nuclear receptor (NR) superfamily, many of which are 
ligand activated transcription factors that bind and respond to a wide variety of 
ligands.  Furthermore there degrees of commonality across all members, through the 
presence of a number of key elements that include a central DNA binding domain 
(DBD) which allow the targeting of DNA response elements.  Towards the C terminal 
of the nuclear receptor protein lies the ligand-binding domain (LBD), lending the 
capacity to associate with ligand and ensure the specificity and selectivity of 
physiological response.  
 
 The effect nuclear receptors exert on transcriptional activity is directly mediated 
through the recruitment of co regulators and transcriptional machinery to towards the 
start site of target genes.  When nuclear receptors are not bound to activating ligands, 
most are associated with co repressors such as nuclear receptor co repressor 1 (N-
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CoR-1) or silencing modifiers for retinoid and thyroid hormone receptors (SMRT) 
allowing further recruitment of deacetylases, therefore tightening chromatin structure 
resulting in transcriptional repression.  
Upon ligand binding the nuclear receptor undergoes conformational changes shifting 
the receptor to a transcriptionally active state allowing association with co activators 
such as histone acetyltransferase allowing further recruitment of transcription factors 
to associated at bind at the transcriptional start site of the target gene (Rastinejad et 
al., 2013).   
These protein complexes allow for the unraveling of the chromatin super structure 
enabling the recruitment of a number of transcription factors associated with the 
formation of the pre-initiation complex.  This overall recruitment of co activators to 
the promoter of target genes causes chromatin unwinding and transcriptional 









Figure 1.4: Schematic representation of a nuclear receptor.  Most nuclear 
receptors are comprised of number functional domains. The conserved DNA-
binding domain (DBD) is responsible for the recognition of specific DNA 
sequences.  Whereas the E domain contains the ligand binding domain 
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1.10 Hormone response elements 
Hormone response elements are sections of DNA that contain conformational 
signatures that are used to control chromatin binding and accessibility to DNA 
response elements within target genes (Umesono et al., 1991). The allosteric effects of 
DNA response elements on nuclear receptor function are essential for differential 
gene expression (Sever and Glass, 2013).    
Dimeric response sites can be configured as palindromes either inverted (IPs) or 
direct (DRs).  These are generated through a series of diverse genome wide repeats 
derived from transposable elements.  A number of nuclear receptors including VDR 
recognize a direct repeat palindrome separated by three nucleotide base (DR3) this 
formation presents optimal binding for the VDR: RXR complex suggesting that the 
asymmetry of the conformation provides the most efficient interface for the DNA 
binding domain of nuclear receptor complex to interact with, making the DR3 
response element the predominant and preferential form of binding the VDR: RXR 
heterodimer (Orlov et al., 2012).  
1.10.1 Nuclear Hormone Receptors PXR & VDR 
All nuclear receptors play a key role in maintaining adequate levels of expression of 
key regulatory genes concerned with such fundamental processes that include cellular 
proliferation, differentiation, metabolism and immune response (Sonoda et al., 2008).  
The NR family also encode for a number of metabolic sensors and regulators 
including the pregnane X receptor (PXR).  Many nuclear receptors members control a 
number of central pathways having fundamental repercussions within a wide range of 
pathophysiology’s including cancers and metabolic disease states.  Nuclear hormone 
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Receptors have a high conserved ligand-binding domain with a great range of genes 
influenced through their activation.  It is this trait that has led much research into 
defining specific ligands to up regulate a certain number of key genes without 
affecting the expression of others (Huang et al., 2010). 
The nuclear receptor superfamily is further sub classified into four smaller families 














Figure 1.5: Summarizes the subdivisions of the nuclear receptor superfamily 
based on ligand binding and dimerization properties.  
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The sub class of interest within this thesis is that which includes the RXR-containing 
heterodimers.  This sub family of nuclear receptor include such members as PXR, 
constitutive androstane receptor (CAR) and Farnesoid X receptor (FXR).  The 
importance of this sub family of nuclear receptors is their importance in overall 
metabolism within the body.  PXR is highly expressed within the liver and intestine 
and therefore plays an integral role in xenobiotic and endobiotic metabolism through 
the regulation of drug metabolizing enzymes and transporters.   
PXR fulfills this role through the binding of DNA response elements as a heterodimer 
with the RXR leading the recruitment of a host of co-activators to the transcriptional 
start site of target genes.  PXR has been deemed the master regulator of metabolism 
due to PXRs ability to be activated by a wide variety of agonists and indeed having a 
broad range of down stream implications as a result, ranging from drug metabolism, 
drug-drug interactions to the homeostasis of a number endobiotics such as glucose, 
steroids, lipids, bile acids, bilirubin and retinoic acid (Ihunnah et al., 2011). 
 
Xenobiotic metabolism is the biochemical manipulation and further modification of 
substrates catalysed through enzymatic regulated activity; In essence it is the 
conversion of hydrophobic substrates to more hydrophilic metabolites allowing for 
the eventual excretion from the body (Guengerich, 2001). 
The term “xenobiotic” comes from the Greek xenos for “stranger” and biotic meaning 
“living beings”.  The phases of metabolism combines to form a complex network of 
inter relating metabolic pathways that modify the chemical structure of xeno and 
endobiotics, including drugs, steroids and mutagens (Watkins, 1990).  These 
pathways come together in the core process of biotransformation and are present in all 
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groups of organisms within the phylogenetic tree of evolution (Caetano-Anollés et al., 
2009).        
The net result of biotransformation in the context of xenobiotic metabolism is the 
overall detoxification of potentially hazardous substrates.  However it must be noted 
that a number of intermediate metabolites can be more hazardous than the parent 
substrate causing more harm as a result of metabolic transformation (Meyer, 1996).  
The fundamental processes that governs xenobiotic metabolism are of particular 
interest to researchers developing personalized medicine tactics, allowing for the 
achievement of individually tailored treatments (Jackson and Chester, 2015), 
(Chalmers et al., 2013).    
 
Many of the substances hazardous to the body are highly lipophilic; this attribute 
allows for the diffusion across cellular membranes enabling the substrates to reach the 
effector target site (Xu et al., 2005).  The process of metabolic clearance has evolved 
to a point in which it is sub divided into three distinct phases; all of which work in 
unison to facilitate the efficient modification and efflux of substrates from the body 
(Rushmore and Kong, 2002).   
1.11 PXR in xenobiotic metabolism   
The most well established function of PXR is to act as a xenosensor in the biological 
protection against exogenous chemicals.  PXR is highly expressed in the liver, kidney 
and intestine with lower expression levels witnessed in other peripheral tissues 
including breast, brain, heart, bone marrow and monocytes (Zhang et al., 1999).  It is 
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this broad spectrum of locals as sites of expression that allows PXR to be well suited 
to play its role through the induction of detoxifying enzymes and transporters. 
1.11.1 Phase I 
Efficient metabolism of exogenous and endogenous compounds is essential for 
normal physiological functioning and as such PXR has the ability to modulate these 
process through induction of phase I cytochrome P450 enzymes (CYPs).  CYPs are a 
superfamily of haem dependent monooxygenases that catalyze the first steps in the 
detoxification of lipophilic compounds (Poulos, 2004).  CYPs are highly expressed in 
the liver and intestine and use hydroxylation reactions to convert target compounds 
into more water-soluble metabolites that are more easily excreted from the body 
(Lehmann et al., 1998a). 
Since PXR has the ability to control the transcription of a large number of CYPs 
including but not limited to CYP3A4, CYP3A5, it stands to reason that it must be able 
to be activated by a huge range of xenobiotic compounds.  PXR has indeed been 
shown to be activated by a large range of pharmaceutical drugs as well as a wide 
range of environmental pollutants (Chang, 2009).  It is interesting to note that PXR 
however does not have the capacity to regulate CYP24A1 this is supported through the 
works Kenneth Thummel, (Zheng et al., 2012), furthermore the work contained 
within this thesis further corroborates the lack of regulatory ability PXR has over 





1.11.2 Regulation of Phase II enzymes     
PXR has also been shown to regulate phase II metabolism-related genes including 
UDP-glucuronosyl transferase (UGT), sulfotransferase (SULT) and glutathione S-
transferase (GST) enzymes.  These phase II metabolic enzymes add on polar 
molecules xenobiotics/endobiotics producing water-soluble metabolites.  A major role 
of PXR mediated phase II metabolic enzyme regulations is the metabolism and 
subsequent detoxification of bile acids, thyroxin, xenobiotics, oestrogens, and 
carcinogens (Xie et al., 2003).  
 
1.11.3 PXR and drug transporters (Phase III) 
Xenobiotic metabolism and disposition are also regulated by cellular uptake and 
efflux transporters controlling intestinal and hepatic absorption, as well as renal re-
absorption, along with biliary and urinary excretion.  These phase III transporters 
work in close concert with phase I and II systems creating an efficient and effective 
metabolic pathway.  The ATP binding cassette family (ABC) are the major 
transporters regulating by PXR, and are expressed in hepatocytes, kidney, enterocytes 
and regulate the cellular movement of drugs in and out of cells.  Examples of PXR 
targeted ABC transporters include multi drug resistance 1 or p-glycoprotein 



















As detailed above PXR plays a fundamental role on the ability of the body to protect 
against xenobiotic and endobiotic assault.  The vitamin D receptor is another member 
of the nuclear receptor sub family and as such shares approximately 95% homology 
with PXR.  Due to PXRs ability to widely influence the expression of a range of 
metabolic and detoxification genes associated with all three phases of metabolism and 
due to the closeness its genetic composition between itself and its family member 
VDR possess, does VDR have the same capabilities as PXR to regulate metabolic 
gene expression across all three phases of metabolism?   
Figure 1.6: Summary of the transcriptional pathways associated with PXR 
activation sourced from (Ihunnah et al., 2011) 
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The evolution and origins of the nuclear receptor subfamily that includes PXR and 
VDR is still under intense research and debate.  However it does appear very probable 
that a single nuclear receptor gene duplicated early in vertebrate evolution.  These two 
genes then diverged from each other to become VDR and PXR that we find.  Further 
mutations and duplications have resulted in multiple PXR and VDR variants 
expressed among a number of different species.    
From the phylogenic study of nuclear receptors it is well established that that nuclear 
receptors emerged long before the divergence of vertebrates and invertebrates.  Since 
the advent of the human genome project and the genetic sequencing of the entire 
human genome 48 nuclear receptor genes have been identified (Zhang et al., 2004).   
Phylogenetic tree of nuclear receptors resulted in the classification of human nuclear 
receptors into six evolutionary groups.  The largest group contains the receptors VDR 
(NR1I1) and PXR (NR1I2) along with other VDR-like members (Evans and 
Mangelsdorf, 2014).  A key similarity exists between each of the DNA binding sites 
among the members of the phylogenetic tree.  There is an ancestral link between the 
evolution of PXR and VDR that remains of great interest.  The close homology seen 
between these two nuclear receptors allows for the postulation of potential cross talk 
and direct interaction between nuclear receptor binding sites with the potential of 
DNA sites being shared between the receptors.  This relationship has not been 
researched in great detail and remains a key and fundamental area of research 







1.12 Gene targeting by VDR 
As previously discussed the classical role of 1,25(OH)2D3 and VDR is the regulation 
of calcium/phosphate homeostasis and bone mineralization.  
Microarray analysis has indicated that between two and six hundred genes are targets 
of the vitamin D receptor and respond in a cell specific fashion.  Through genome 
wide analysis more that 1600 Vitamin D response elements (from this point known as 
VDRE) have been identified (Hii and Ferrante, 2016).  
VDR has been seen to regulate the expression of the major calcium channel gene 
within the intestine, TRPV6, as well as the sodium phosphate transport protein 
Figure 1.7: Phylogeny of PXR highlighting functional characteristics and close 
relationship between VDR and PXR sourced from (Iyer et al., 2006) 
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SLC34A2. Further VDR targets include the up regulation of the fibroblast growth 
factor FGF23, discussed previously.  VDR has also been seen to induce tumour 
necrosis factor RANKL leading to increased oesteoclast formation (Barthel et al., 
2007). 
The most responsive VDR-target gene identified to date remains CYP24A1, whose 
enzymatic gene product is key to the catabolism of 1,25(OH)2D3.  The activation of 
this gene generates a negative feedback loop controlling the levels of circulating 
vitamin D.  VDR binds preferentially to a vitamin D response element consisting of 
two hexanucleotide (AGGTCA or similar) direct repeats, separated by a three 
nucleotide spacer; direct repeat 3 or DR3.  Furthermore an everted repeat of the 
hexanucleotide motif with a six nucleotide spacer (everted repeat 6; ER6)is an 
additional configuration that allows VDR binding.  A number of VDREs, including 
DR4, ER7, 8 and 9 motifs have been identified in cyclin c and insulin like growth 
factor binding protein.  In addition gene involved in inflammatory pathways, and cell 
growth such as tumour necrosis factor alpha, interlukin 2 and c-Myc are negatively 
regulated by VDR activation.  It is therefore imperative that our understanding of 
gene regulation of VDR is well understood and established as the potential 
therapeutic effects of VDR ligands in the treatment of cancer and autoimmune 
diseases are based on both positive and negative regulation of target genes (Saramäki 





1.12.1 VDR and metabolic gene regulation 
VDR also has an effect on other metabolic gene members of the Cytochrome p450 
family.  CYP3A4 contains a DR3 motif as well as an everted ER6 proximal to the start 
site of the gene and has been shown to be greatly induced through the activity of VDR 
binding (Thompson et al., 2002) and has been considered a primary target of VDR 
activity.  Due to the ability of VDR to impact on the transcriptional activity of 
CYP3A4, VDR may have an impact on the metabolism of prescription drugs as 
CYP3A4 is involved in the metabolism of over 60% of drugs available today as will 
be discussed in later chapters.  Furthermore VDR has the ability to act as an intestinal 
bile acid sensor, as secondary bile acids have shown affinity towards VDR binding 
(Chiang, 2009).  The ability of VDR to bind secondary bile acids gives the potential 
for effective turn over/metabolism of potentially harmful substrates, expediting their 
removal from the lower intestinal tract.   
 
Further investigation is required into the precise role VDR has over the transcriptional 
activity of metabolic gene activity, as this area has not yet been fully explored.  VDR 
has been shown to affect phase one metabolic genes, as well as phase three in the 
form of members of the ATP binding cassette (ABC) superfamily, and multi drug 
resistance proteins all of which are involved in the expulsion of xenobiotics from 
cellular compartments including P-glycoprotein and MDR1 (Saeki et al., 2008).  To 
this end very little research has been conducted in the area of phase two metabolism, 
and the potential role VDR may have at controlling gene activity. 
 
 43 
Phased metabolism is regulated through the activity of nuclear receptors such as PXR 
and CAR.  PXR and VDR share approximately 90% homology with each other.  
Furthermore PXR and CAR are already established inducers of phase two metabolic 
gene activity; however nothing is documented on the ability of VDR to regulate UGT 
gene expression.  The major family of genes within phase two metabolism is Uridine 
5’-diphospho-glucuronosyltransferase (UGT) and it is this family of genes that will be 
the focus of this thesis.  
 
1.13 Phase II metabolism and UGTs 
Phase II metabolism is characterized through conjugation reactions, with the use of 
glucuronic acid or sulphate groups that drastically increase the molecular weight and 
therefore the water solubility of the metabolized substrate.  This conjugation system 
aids in eventual removal of metabolites from the body (Jancova et al., 2010). 
Cytochrome P450 (phase one) and Uridine 5’-diphospho-glucuronosyltransferase 
(UGT, phase two) work in conjunction with each other to form easily excretable 
glucuronides metabolites, through conjugation with glucuronic acid (Guillemette, 
2003).  The original isolated glucuronides can be traced back to rural India in the 
acquisition of the Indian yellow dye attributed to Schmidt in 1855.  The dye is a 
glycoside and is a conjugate of the aglycone euxanthone with glucuronic acid 
generating the more water-soluble chromophore.  As with the majority of phase one 
proteins; phase two enzyme production and activity was discovered to be highly 
localized in the liver by Lipschitz and Bueding et al.   
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UGTs where later localized to the microsomal fraction of cell lysates, and it was then 
hypothesized that UGT proteins resided within the endoplasmic reticulum (Ikushiro et 
al., 1997), a finding later confirmed by Shepherd et al 1989.  It was during this time of 
discovery that the roles of UGTs within the body where being discovered.  
Glucuronide formation through UGT activity was driven towards a number of 
endogenous hormones, steroids and pharmaceutical drugs including paracetamol, 
morphine, and phenobarbitone (Fisher et al., 2001), (Crettol et al., 2010), (De Gregori 
et al., 2012).   
The most important discovery of UGTs was the identification that these proteins 
where the sole enzyme involved in the detoxification of bilirubin in 1956 (Sticova and 
Jirsa, 2013).  Bilirubin is a breakdown product of haemoglobin, which, when unbound 
can cause unconjugated hyperbilirubinaemia, and if left untreated can lead to neuronal 
toxicity and eventual death (Tukey and Strassburg, 2000), (Fujiwara et al., 2010).   
During the early years of UGT discovery it was postulated that there was only one 
UGT enzyme that had a promiscuous activation domain, which was responsible for 
the wide range of conjugation events within the body (Strassburg et al., 1997b).  
However this was contradicted by other researchers who hypothesized the 
heterogeneity of the UGT proteins was due to the presence and activity of many 
transferase enzymes not just a single enzyme; therefore each transferase had varying 
degrees of binding affinity depending on the substrate being conjugated.  This line of 
reasoning was supported by the works of Kasper and Gorski et al who developed a 
range of affinity chromatography techniques allowing for the purification of UGT 
proteins.  This in addition to the work of (Tukey and Strassburg)allowed for the 
confirmation that UGT proteins are integrated into the endoplasmic reticulum 
membrane.  With this increase in understanding and a clear method developed to 
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purify homogenous and active UGT proteins, resulted in the isolation of substrate 
specific UGTs for a range of steroids found within the body including oestrogens, 
testosterones (Guillemette et al., 2004).  This research culminated in the proposal that 
there is a heterogeneous population of UGTs.  
With this proposal in mind a number of mouse and rat UGT isoforms were identified 
providing clear evidence for the heterogeneity of UGT family of genes.  In 1991 the 
first series of UGT nomenclature was published.  Many of the UGT isoforms share 
>80% homology however a clear presence of two distinct UGT families exists: UGT1 
and UGT2.   
The UGT1A locus is located on chromosome 2 and comprises thirteen distinct first 














Figure 1.8: The UGT1A gene spans 220 kilo bases located within chromosome 2q37 and contains 13 cassette exons.  There are 
a total of 9 functional exons each with unique regulatory promoter regions enabling independent RNA transcription, and 4 
pseudogenes (p).  The process by which each unique primary transcript is generated is referred to as exon sharing. Adapted from 
(Tukey and Strassburg, 2000). 
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UGT1A expression is a highly controlled, and expressed in a tissue specific manner 
with the majority of expression present in the liver however other tissues of note 
include the colon, kidney, intestine and brain (Zhang et al., 2007).  The liver has long 
been designated the major organ associated with metabolism and this is further 
supported by the abundant expression of genes across all three phases of metabolism 
present throughout hepatic tissue including CYP3A4 and CYP3A5 (Kuehl et al., 
2001).  The liver expresses many members of the UGT1A family including A1, A3, 
A4, A6, A9.  The latter four members are expressed in a solely extra hepatic manner 
(Strassburg et al., 1997).  It is now understood that the UGT1A family of genes 
undergo epigenetic regulation through methylation events aiding in tissue specific 
expression (Choudhuri et al., 2010).  This holds true for UGT1A expression in the 
kidney.  The UGT1A1 gene is hyper methylated, silencing the expression of the gene 
within the tissue (Oda et al., 2013).  In contrast the colon has the most abundant 
isoform expression second only to the liver, expressing all the UGT1A isoforms 
except UGT1A7 which is localized to the upper intestinal tract.  Further UGT1A 
specificity is highlighted in the brain, and is thought to be involved in the metabolism 
of certain neuronal hormones such as serotonin as well as xenobiotic substrates 
including morphine (Ohno et al., 2008), (Armstrong and Cozza).   
UGT1A1 is the sole metabolizer of bilirubin within the body and as such is associated 
with a number of genetic disease phenotypes, a number of which if left untreated can 
be fatal (Kamisako et al., 2000).  Evidence also supports the increased risk factors 
UGT1A1 polymorphisms may have on the development of coronary heart disease and 
diabetes (Lingenhel et al., 2008). 
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1.14 UGTs and bilirubin 
Bilirubin is the breakdown product of aged erythrocytes and therefore a result of 
haem metabolism.  Bilirubin is generated through the activity of biliverdin reductase 
on biliverdin lending bilirubin to have anti oxidative properties within a biological 
system (Sticova and Jirsa, 2013). 
As with most endogenous substrates bilirubin is metabolized within the liver and as 
such is known as conjugated or direct bilirubin depending on the measurement being 
assessed (Shiomi et al., 1999).  The process of conjugation with glucuronic acid 
makes the resulting metabolite more hydrophilic in nature lending itself to increased 
water solubility.  The conjugated metabolite then moves into the small intestine were 
bile acid reabsorption occurs via the enterohepatic circulation (Lester et al., 1961), 
direct bilirubin however passes through into the colon, and is not reabsorbed. 
1.15 UGTs in disease 
 
The UGT1A family of enzymes play important roles in metabolism and as such a 
disruption in these enzymes results in disease states of varying degrees of complexity.   
Interruption of UGT1A1 can result in high levels of circulating bilirubin known and 
hyperbilirubinaemia.  The most common genetic variation in UGT1A1 is an elongated 
TATA sequence within the proximal promoter manifesting phenotypically as 





1.15.1 Gilbert’s Syndrome (UGT1A1*28) 
Gilbert’s Syndrome is a hereditary and chronic presence of elevated unconjugated 
bilirubin levels as a result of impaired hepatic bilirubin clearance that can lead to 
jaundice under certain stresses including infection and fasting, but otherwise the 
condition is usually asymptomatic with normal liver functionality.  The disease was 
first documented in 1901 but the main characteristics of the syndrome where not 
described until 1920 by a German physician Meulengracht coining the term icterus 
interminus juvenilis.  With this mutation present the activity of the UGT1A1 enzyme 
is reduced to 30%, resulting in a 70% overall reduction in the livers ability to 
conjugate bilirubin (Radu and Atsmon, 2001).  
1.15.2 Crigler-Najjar Syndrome 
Crigler-Najjar Syndrome is a rare autosomal recessive disorder and like Gilberts 
Syndrome has a detrimental inability to metabolize bilirubin.  It is subdivided into 
two categories, with each subclass having distinct yet similar features. Type I and II 
Crigler-Najjars sufferers have very distinct phenotypes.  Type I sufferers exhibit 
intense jaundice and is seen soon after birth remaining thereafter (Jansen, 1999), (Nair 
et al., 2012).  A complete lack of UGT1A1 expression also accompanies the disease 
with a percentage of sufferers having a mutation within the common exons (2 to 5) 
leading to an inability to metabolize phenobarbital as well as a range of other drugs 
and xenobiotics (Trotman et al., 1983).  Children who are diagnosed with this genetic 
disease are at risk of developing bilirubin encephalopathy accompanied with many 
other complications including deafness, ocular palsy and lethargy.  The risk of 
neurological defects can be very serious and has been documented to affect the basal 
ganglia and hippocampus (Gourley, 1997).    
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Type II, results in a milder manifestation of hyperbilirubinaemia that does respond to 
phenobarbital treatment a known prototypical ligand dependent activator of UGT1A1.  
1.16 Xenobiotic Regulation of UGTs 
UGTs are highly tissue specific in nature as indicated through varying degrees of 
expression seen throughout the human body; to this end adding an additional tier of 
complexity is the ability of xenobiotics to regulate UGT activity through the binding 
and subsequent activation of a large number of allelic polymorphisms found within 
UGTs, allowing for the determination of individuals glucuronidation profiles (Kim et 
al., 2014).   
A number of early studies focused on localized transcription factors within the liver as 
the prime source of UGT activity.  Liver rich transcription factors such as the 
hepatocyte nuclear factors or (HNFs), has been shown to be an essential requirement 
of a number of UGTs found within the liver such as UGT1A3 and 1A4 (Gardner-
Stephen and Mackenzie, 2007).  Conserved response elements have been mapped 
highlighting palindromic motifs within a number of key UGT1A family members. 
UGT dependence on HNF as pre requisite for activation in a number of circumstances 
indicates the transcription factors play a pivotal role in the cross regulation of 







1.17 Conclusion & aims 
UGT1A1 has been shown to play a key role in hepatic metabolism through its ability 
to metabolism bilirubin as well as other xenobiotic substrates including 
chemotherapeutics and painkillers.  However the extra hepatic role of UGT1A 
remains unclear and the potential for its expression to be modulated through the 
activities of the nuclear hormone receptor VDR to regulate its expression has not been 
documented before.   
 Therefore, the aims of this thesis can be categorized as follows: 
- Identify which members of the UGT1A family are directly regulated by VDR. 
- Establish the effectiveness of VDR activation through comparison to known 
and established prototypical inducers.  
- Delineate the mechanistic action of VDR targeted UGT1A members, through 
analysis of novel vitamin D response elements within the promoter/enhancer 
module regions.     
- Assess further the potential implications VDR regulation could have on 














Chapter 2: Expression Analysis of Detoxification Genes 

















The liver has long been established as the major detoxification organ associated with 
toxin, steroid, and xenobiotic transformation (Almazroo et al., 2017).  However more 
evidence brought to light the important role that intestinal detoxification plays within 
the bodies overall ability to metabolize potential harmful substrates (Li and Apte, 
2015).  Metabolism beyond hepatic tissue remains a relatively new area of study, 
however much research is now geared towards the potential protective roles intestine; 
small, large and colonic sources could play in genome wide protection against 
carcinogenic and environmental assault.  To this end, a deeper understanding of 
metabolic control is required to clearly understand hepatic and extra hepatic roles.  
Nuclear receptors are long been known to facilitate the homeostatic regulatory 
balance within the liver, and indeed their role far surpasses that of a hepatic nature.  
Vitamin D and by extension the Vitamin D Receptor (VDR), is known to play 
classical roles in calcium and phosphate ion homeostasis ultimately effecting bone 
mineralization, strength and formation (Veldurthy et al., 2016).  This functional role 
that vitamin D plays within the skeletal system was once thought to be its only major 
role.  This line of thought was entirely accepted until VDR was cloned from a 
primitive fish lacking the ability to mineralize tissue (Doherty et al., 2015).  This in 
itself led to speculation over the potential role VDR has beyond that of bone 
mineralization. Our understanding of VDR is ever increasing; its role within the 
overall detoxification goes beyond that of the liver and expands into all three phases 
of metabolism. Many target genes have been identified over the past decade involved 
in detoxification events. VDRs ability to regulate detoxification events outside the 
primary hepatic environment is supported through the observation that VDR can be 
activated and elicit a transcriptional response whilst bound to secondary bile acids 
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such as lithocholic acid and its derivatives supports the role the VDR may play in 
detoxification within biliary (major site of bile acid transport), intestinal and colonic 
tissue environments (Ogura et al., 2009),  (Han et al., 2010) .       
2.2 Hepatic metabolism 
The historical source and key organ associated with environmental, and 
pharmaceutical detoxification remains the liver.  Within hepatic tissues resides a 
network of phased metabolic systems working in concert to achieve efficient removal 
of potentially harmful substrates from the body.  It is only through these three 
metabolic systems working together, can toxins be metabolized in a fashion that limits 
the damage potential of the metabolizing substrate (Strnad et al., 2017), (Xu et al., 
2005). 
All three phases of metabolism are controlled through the actions of nuclear receptors 
that are superfamily of metabolic and endocrine sensors with the ability to activate 
and repress transcriptional responsiveness of target genes depending on the hepatic 
environment at the time. 
 
2.3 Nuclear receptor control of hepatic & enterohepatic metabolism 
Nuclear receptors are primarily ligand activated transcription factors involved in a 
wide range of processes within the cell.  In the hepatic and enterohepatic circulation, 
bile acids and derivatives of such, act as agonists for nuclear receptors eliciting 
transcriptional responses from target genes involved in the elimination and further 
metabolism of such substrates as primary bile acids (BA) and cholesterols.  LXR and 
FXR play key roles in maintaining bile acid levels within the body and it is through 
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BA binding of nuclear receptors like FXR that lead to an up regulation of CYP450 
members in an attempt to increase the metabolic turnover of primary BA 
accumulation.  FXR remains the key metabolic sensor associated with BA 
metabolism within the liver and intestine (Gonzalez et al., 2016).  All of the class I 
nuclear receptors perform their actions with the heterodimeric partner RXR alpha, this 
indeed holds true for additional members including PXR and VDR.  Due to the close 
homology shared among nuclear receptor members, secondary bile acids have been 
seen to elicit VDR responsiveness, suggesting a potential role in maintaining a 
homeostatic balance within the enterohepatic circulation and other tissues outside the 
liver as VDR has limited expression in hepatocytes (Zollner et al., 2006). 
This master control of many metabolic related genes gives PXR unprecedented 
control over hepatic and extra hepatic metabolism.  This is evidenced through the 
ability of PXR to control bile acid metabolism.  When LCA binds to PXR it results in 
the increase in expression of CYP3A members allowing for hydroxylation events to 
take place, facilitating the conversion of the metabolic substrate to be more 
hydrophilic in nature, allowing for the re entry into the circulation as a secondary bile 
acid or primes the metabolite for further transformation for rapid clearance from the 
body through the urine of faeces.   This up regulation of CYP3A activity is thought to 
be an adaptive, protective response to potentially harmful levels of bile acid 
accumulation.  PXR, CAR, and FXR act concordantly to mediate the exposure of 
liver to bile acid assault.  PXR, CAR and FXR have been seen to induce the 
expression of UGT1A members within the liver as a result if BA binding facilitating 
the addition of a glucuronile group to the substrate.  The ability of VDR in this 
instance remains extra hepatic in nature, as VDR is not highly expressed within the 
liver, however VDR has been seen to control detoxification genes outside the liver 
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including genes involved in phase I (CYP450) and III (drug efflux proteins; ABCB1), 
(Tachibana et al., 2009), (Chae et al., 2016).  
Therefore if VDR has the ability to regulate metabolic genes within phase one and 
three pathways, to what extend does VDRs control play in phase two systems?        
 
2.4 Extra hepatic detoxification & VDR expression 
 VDR is not highly expressed within core hepatocytes that make up greater than 90% 
of the livers mass however stellate, biliary epithelial cells, kupffer cells and sinusoidal 
endothelial cells all express higher levels of the vitamin D receptor.  The extra hepatic 
expression and metabolism remains an area of key interest to those investigating the 
role of VDR in overall metabolism and detoxification. Tissue specific expression of 
VDR within cells outside of the liver suggest that the liver as a whole could be 
responsive to vitamin D.  This hypothesis is supported through hepatic stellate cells 
expressing high levels of VDR furthermore stellate cell have been recently shown to 
repress TGF-Beta activation (Ding et al., 2013). VDR expression has been seen to be 
expressed throughout the body and have implication on disease pathophysiology 
including Crohn’s, IBD and diabetes (Cantorna, 2006).  Intestinal and colonic 
expression has been of great interest in recent years, and impairment of VDR 
expression within these tissues has been linked with disease progression including 
Crohn’s disease (White, 2016) , colorectal cancers (Thompson et al., 2002c), (Meeker 
et al., 2016) and inflammatory bowel disease (Froicu et al., 2003), (Kong et al., 2008).  
Indeed, mouse model studies have shown that VDR-null mice can be rescued from 
severe intestinal colitis and death with the introduction of hVDR transgene intestinal 
epithelial cells (Liu et al.).  The epithelial expression of VDR has been shown to 
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inhibit inflammatory pathways such as NF-kB, with an overall reduction in pro 
apoptotic pathways.  With the ability of VDR going beyond what was once thought to 
be it’s only role within the body, that of bone mineralization through calcium and 
phosphate homeostasis, allows further questions to be sought.  The nuance of VDRs 
ability to effect disease progression is that reduced circulating vitamin D has an 
impact on disease states (Aggarwal and Kallay, 2016).  Vitamin D deficiency has 
been diagnosed in many patients who suffer from inflammatory conditions including 
irritable bowel disease (IBD) and Crohn’s Disease (CD) (Sadeghian et al., 2016).  
VDR expression has been associated with an increase risk of developing 
neurodegenerative disorders such as Alzheimer’s Disease (AD) and therefore vitamin 
D deficiency and by extension VDR expression and activity has been linked with 
disease development and progression.  
 
2.5 UGT1A hepatic expression 
UDP-glucuronosyltransferases (UGT) are phase two metabolism enzymes, and act as 
homeostatic regulators aiding in biotransformation of potentially harmful substrates.  
These enzymes achieve this through conjugation reaction, fusing glucuronic acid to 
the metabolizing substrate ultimately transforming it into a more hydrophilic 
metabolite.  This family of enzymes play major roles in overall detoxification through 
their role in bilirubin metabolism (haem break down product), as well as a wide range 
of other steroids, hormones, and xenobiotics.  As a result a number of nuclear 
receptors including PXR, FXR, and CAR have DNA response elements within a wide 
number of the UGT1A gene family members proximal and distal promoters, and it is 
the presence of all these response elements that lend the UGT1A family of enzymes to 
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be highly inducible in hepatic models such as the HepG2 and HuH7 cell lines 
(Nakamura et al., 2008a) and (Fasinu et al., 2012).  UGT1A1 has been highly 
researched due to its major and sole role in bilirubin metabolism, a number of KO 
mouse models have been generated allowing for further investigative analysis of the 
role UGT1A1 plays in the overall detoxification pathways within a biological system.  
Polymorphisms within the UGT1A1 genes have also been linked with disease states 
including Gilberts Syndrome (UGT1A1*28), phenotypically manifesting as 
hyperbilirubinaemia, due to impairment in the catalytic activity of the UGT1A1 gene.  
This also has further implications towards the ability of UGT1A1 to act upon other 
exogenous and endogenous substrates including Irinotecan and morphine.                 
 
2.6 UGT1A1 intestinal expression 
The extra hepatic expression of UGT1A1 remains an area of keen interest for many 
researchers.  It has been seen; mouse models with a K.O. of hepatic UGT1A1 
expression exhibit a compensatory strategy with regards intestinal UGT1A1 
expression.  Furthermore a selective K.O. of intestinal expression results in the 
cessation of life within the animal model paradigm (Chen et al., 2013).  This further 
indicates the potential importance intestinal expression of UGT1A1 could have in base 
line survival and genome wide protection against external and internal assault.  
Cancer of the gastrointestinal tract shows a marked reduction on metabolically active 
genes including members of the UGT1A family (Vogel et al., 2002), (Drozdzik and 
Oswald, 2016).  Efficacy of Irinotecan metabolism is also affected with impairment of 
UGT1A1 intestinal activity.  A reduction in intestinal expression has also been noted 
to lead to the development of hyperbilirubinaemia and a condition known as bilirubin 
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induced neurologic dysfunction (BIND).  BIND is characterized as a toxic build up 
bilirubin in the brain most commonly seen in neonates ultimately leading to 
neurotoxicity if left untreated.           
In this chapter the focus will be to evaluate if the vitamin D receptor can influence the 
transcriptional expression levels in; an enteric cell model (LS180) and hepatic cell 
model (HepG2) following exposure to a number of VDR agonists.  In addition to this 
we want to further delineate if activation via VDR ligands are as potent inducers as 
previously identified agonist of UGT1A activity, as mediated through PXR activation.  
This will be achieved through a number of PCR based approaches allowing for both a 
qualitative and quantitative view to be established and assessed.  In addition to this 
vector transfection studies will be employed to delineate further which specific 
members of the UGT1A family are regulated through VDR activity, using known and 
established nuclear receptors as a comparison in both hepatic and extra hepatic 






























2.2.1 Cell Culture  
All cell lines used within this research where obtained from the American Type 
Culture Collection (ATCC), (Rockville, MD, USA), unless otherwise stated.  
2.2.2 LS180 cell line model & maintenance 
The LS180 cell line was kindly gifted to the Thompson lab by Professor J Wesley 
Pike (Madison, Wisconsin).  These cells were maintained in Minimum Essential 
Media (MEM), 10% foetal bovine serum, 1% sodium pyruvate, 1% non-essential 
amino acids, and 1% penicillin/streptomycin (Gibco, Paisley, UK). The LS180 cell 
line model is a well-established and highly used epithelial colonic adenocarcinoma 
model and represents an excellent cell line for exploring underlying transcriptional 
mechanisms as the mRNA output from these cells are abundant and highly 
reproducible.   
2.2.3 LS180 passaging 
The cells were washed with PBS and incubated with Minimum Essential Media 
containing 1M EDTA (10ml media: 50μl EDTA).  The cells were then replaced back 
into 37°C, 5% CO2 and 95% air, with humidified atmosphere and allowed to incubate 
for between 3 and 5 minutes, no longer as EDTA can become toxic if left on cells for 
an extended period of time.  To ensure complete removal of the cells from the flask a 






2.2.4 HepG2 cell line model & maintenance     
The HepG2 cell line has been used within the research to represent a liver cell model.  
The cell line is derived from a hepatocellular carcinoma and is again epithelial in 
nature.  The cells were maintained in Dulbecco’s Modified Eagles Media (DMEM), 
high glucose (4.5g), supplemented with 15% foetal bovine serum, and 1% 
penicillin/streptomycin (Gibco, Paisley, UK). 
All medias and supplements detailed above were sourced from GIBCO (Invitrogen, 
Paisley, UK), unless otherwise stated.   
 
2.2.5 HepG2 cell passaging using trypsin dissociation 
Complete growth media was removed and the cell monolayer was washed with 1x 
Phosphate Buffered Saline (PBS) (Oxid, Hampshire, UK), to remove any residual 
growth media from the flask.  5ml of 1 x Trypsin was added to the flask and allowed 
to incubate for 3-5 minutes at 37°C, 5% CO2 and 95% air.  With gentle tapping of the 
flask the adherent cells were dislodged forming a cell suspension.  Double the amount 
of complete growth media was added to the Trypsin and cell suspension, this 
inactivates the Trypsin.  The cell suspension was then centrifuged at 12000rpm for 5 
minutes to create a cell pellet followed by careful removal of the supernatant.  The 
resulting pellet was resuspended in complete growth media to an appropriate dilution 




2.2.6 Cell counting 
To ensure cell viability and cell seeding density throughout all experimental 
procedures a haemocytometer was used to ensure accurate cell counts.   
Cells where collected as outlined above and spun at 12000rpm using a bench top 
centrifuge at room temperature.  The supernatant was carefully removed and the cell 
pellet resuspended in between 5-10ml of complete growth media (depending on the 
size of the cell pellet).  An aliquot (12μl) of the resulting cell suspension was taken 
and mixed 1:1 with Trypan Blue stain (Sigma-Aldrich, Dorset, UK).  The resulting 
stained suspension was then pipetted up and place at the edge of a cover slipped 
haemocytometer, and allowed to flow via capillary action across the counting 
chambers.  Viable cells do not take up the Trypan blue stain therefore allowing for 
cell viability to be determined counting the unstained cells in the outer 4 squares and 
the middle square, viewed under inverted phase contrast light microscopy (40x 
magnification). 
The same process was conducted using the 2nd counting chamber on the 
haemocytometer giving a total of 10 squares counted allow for an average to be 
calculated.  The total number of cells in the suspension from which the aliquot was 
taken was determined using the following equation: cells/ml = (n) x 2 x 104, where   
n = average total number of cells counted in 10 squares, 2 = the dilution factor with 
Trypan blue stain and 104 is the multiplication factor to obtain the number of cells in 




2.2.7 Freezing and thawing cell stocks 
Frozen stocks of all cell lines were prepared as per the ATCC guidelines using either 
95% FBS: 5% Dimethyl Sulfoxide (DMSO) or 95% complete media: 5% DMSO.  A 
175cm3 confluent flask of cells was pelleted and a cell count performed allowing for 
the freezing of 4x106 cells/ml in freeze down solution and placed in -80°C.  For long-
term storage and to ensure no loss in cell viability a number of cryovials were 
subsequently stored in liquid nitrogen.   
Cell thawing was achieved through rapid defrosting using a water bath at 37°C.  
Upon complete defrost of the cell stock the cells were transferred to a universal and 
5ml of complete growth media was added drop wise to the cells and freeze down 
mixture.  The suspension was then spun at 12000rpm for 5 minutes.  The supernatant 
was discarded and the pellet washed in 1x PBS before being resuspended in 1ml of 
complete growth media and transferred to a large 175cm3 flask.  The flask was then 
incubated overnight at 37°C, 5% CO2 and 95% air, and humidified atmosphere.  The 
following day non-adherent, dead cells were washed away using 1x PBS and fresh 








Ligands/Solvents used in Gene Expression Studies 
Ligand/Solvent Final Working Conc. Solvent Source 
Ethanol <0.095% - Rathburn, Scotland 
DMSO <0.099% - Sigma 
Methanol <0.099% - Sigma 
1,25-(OH)2D3 10nM Ethanol Enzo Scientific 
EB1089 10nM, 1nM Ethanol Enzo Scientific 
Bexarotene 1μM Ethanol  
Rifampicin 20μM Methanol Sigma 
GW474064A 1μM DMSO Glaxosmithkline 
T0901317 1μM DMSO Sigma Aldrich 
 
The above table details the ligands and their respective solvents used within the gene 
expression studies.  Each of the ligand treatments are controlled against their 
respective vehicle only counterpart (itemized above) from which to extrapolate fold 
induction of gene expression achieved through exposure to ligand over levels 





2.2.8 RNA extraction & Reverse-Transcriptase Polymerase Chain Reaction (RT-
PCR) 
All gene expression studies were conducted using 6 well plates across all cell types, 
this allowed for adequate isolation of RNA from the cell models used.  When 70% 
confluency was reached cells were washed in 37°C PBS, collected either via trypsin 
disassociation or mechanical removal of cells via a cell scraper, counted and seeded 
and 2-2.5x105 cell/well, depending on cell model used.  Cells were allowed to adhere 
for 24 hours before treatment.  Cells were treated for 24 hours at which point total 
RNA extraction was performed using the Qiagen RNeasy Plus Kit per manufacturers 
protocol (Qiagen, Sussex, UK).  The procedure involved collection of the cells using 
trypsin or cell scraper (cell line dependent), and re suspending the cell pellets in 350μl 
of RLT buffer containing 6μl – β-mercaptoethanol.  The resulting homogenate was 
then passed through a Neolus® 20G needle (Terumo UK, Surrey, UK), 5 times, before 
being expressed into a gDNA eliminator column.  The resulting flow through 
underwent a series of ethanol precipitation and wash steps with the aid of RNA spin 
column technology, the total RNA was eluted into 50μl of RNase-free water.  The 
Total RNA concentration was then determined using the NanoDrop® ND-1000, and 
stored at -80°C.   
cDNA synthesis was performed using SuperScript™ II (Invitrogen, Paisley, UK).  
Between 1-2μg of RNA was used depending on the RNA concentration and quality.  
The RNA was reverse transcribed using random OligoDT12-18 primers (Invitrogen, 
Paisley, UK) using manufacturers protocol.  Total RNA, OligoDT12-18 and dNTPs to a 
final volume of 12μl, were heated to 65°C for 5 minutes.  7.5μl of a master mix made 
up of first strand reaction buffer, 0.1M DTT, and PCR water was added to each 
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sample respectively, before being heated for 2 minutes at 42°C.  Finally, 0.5μl of 
SuperScript II Reverse Transcriptase was added to each sample and placed back on 
the on the heat block for one cycle of 50 minutes at 42°C, and 15 minutes at 72°C 
(inactivation), before holding the samples at 4°C degrees.  All the reverse 
transcription reactions were carried out in 0.2ml PCR tubes on a multi block Techne- 
5000.  The cDNA was subsequently diluted to 10ng/μl using PCR grade water and 
stored at -20°C. 
2.2.9 End Point Polymerase Chain Reaction (End Point-PCR) 
The end point PCR reactions were achieved using the GoTaq® Flexi DNA 
Polymerase technology, (Promega, Madison, USA).  Each reaction mix contains 1 x 
Green Flexi Buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.2μM of sense and antisense 
primers respectively.  To this 15.9μl of PCR grade water was added, along with 0.5μl 
of GoTaq® DNA Polymerase creating a final volume of 25μl.  The resulting PCR 
mixture was spun briefly to ensure all the reagents were at the bottom of the PCR 
tube.   
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) is used within these 
experiments as a housekeeping gene control as this gene is not effected by any of the 







End Point PCR Primers 
Primer  Sense (5’ to 3’) Antisense (5’ to 3’) 
HPRT GACCAGTCAACAGGGGACAT AGCTTGCGACCTTGACCAT 
UGT1A1 GTTGATCCCAGTGGAATGGCAG AAGTGGGAACAGCCAGACAA 
UGT1A3 AGGTGTCAGTGGTGGATATTCT ACAGGACTGTCTGAGGGATTTTG 
UGT1A4 CTGGCTACACTCAAGGGTT TGGCAAATGTAGGACAGGGC 
UGT1A5 GCTGGGTTCACACTCAATCGT CAAAGGTAGGACAGGGCCAG 
UGT1A6 TCAGGGGTTTTCCGTGTCC GGCTTCAAATTCCTGAGACAAGT 
UGT1A7 GTTTTTGCCGATGCTCGCTG GGCAAAATATTCCCCTGGCG 
UGT1A8 GCCCCATTCCCCTATGTGTTTC ATGAATCCCGGTCCAGATCC 
UGT1A9 TCCAACACCTGTTACGGAG CATCGGGTGACCAAGCAGAT 













All end point PCR reactions were as follows: 
Initial Denaturation 2 minutes, 94°C 
Denature 30 seconds, 94°C 
Annealing 30 seconds, 55°C 
Extension 1.15 minutes, 72°C 
Final Extension 10 minutes, 72°C 
Hold 10°C 
   
The cycle number applied to achieve amplification for the listed primer sets were: 
UGT1A10, 40 cycles, HPRT, VDR, PXR and UGT1A4, UGT1A5, UGT1A7, was 
achieved at 35 cycles, UGT1A6, and UGT1A8 at 30 cycles UGT1A1, 27 cycles.  
The PCR products were separate on 1.5% agarose using electrophoresis, 1 x Tris 
Acetate (TAE) buffer, containing 10mg/ml ethidium bromide (Sigma, Dorset, UK).  
The agarose was dissolved in TAE buffer and poured into a casting cassette and 
allowed to solidify at room temperature.  Once the gel was set the comb in removed 
and 1 x TAE is poured into the electrophoresis chamber until the gel is just 
submerged in buffer.  8μl of the appropriate ladder (100bp TrackIt DNA ladder), 
(Invitrogen, Paisley, UK) was loaded, followed by 12μl of each respective sample 
(half the reaction mix).  The gels ran at 100 volts for 20-30 minutes depending on the 
migration speed before visualization under UV light exposure using a Kodak UV 
trans-illuminator.   
 70 
2.2.10 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)  
Quantitative Real Time PCR was used to establish endogenous messenger RNA 
levels of expression of target genes of interest.  Therefore 2.5μl of cDNA (10ng/μl) 
was subject to a PCR reaction using Roche gene specific hydrolysis probes using the 
Roche Light Cycler® 480 analyzer.  The reaction mix is detailed below. 
 
        Volume (μl)   
  - Light Cycler Probes Master Mix  5 
  - Probe     0.5 
  - PCR grade H2O (with kit)   2 
  - cDNA template (10ng/μl)   2.5 μl 
 
Each reaction as described above underwent amplification on the Roche Light 
Cycler® 480.  The thermocycle began with pre incubation at 95°C for 10 minutes 
followed by amplification for 50 cycles at 95°C for 10 seconds, 60°C for 30 seconds, 
72°C for 1 second followed by a final cooling step at 40°C for 30 seconds.  Once the 
PCR run was complete the raw Cp values underwent relative quantification using the 
built in analysis tools provided by Roche for data analysis, employed also was the 
Delta/Delta Ct methodology.  This method of analysis was devised by Kenneth Livak 
and Thomas Schmittgen in 2001 and has been used and cited over 61,000 times.  In 
brief the cycle threshold or Ct is the cycle number when the florescence generated by 
the PCR reaction is distinguishable from background interference or noise.  The Delta 
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Ct is the difference in Ct values for the target gene of interest and the housekeeping 
gene (HPRT).  This rationale normalized the gene of interest to a gene that is not 
affected by the experimental set up and procedure allowing for fold change to be 





















Hydrolysis Probe Cat RealTime Ready ID Hydrolysis Probe Cat RealTime Ready ID 
HPRT 102079 UGT1A7 145839 
CYP3A4 135760 UGT1A8 145843 
CYP3A5 112269 UGT1A10 145837 
CYP24A1 114955   
TRPV6 110452   
UGT1A1 138404   
UGT1A3 140686   
UGT1A4 140612   
UGT1A5 145870   
RealTime ready Probe used in qRT-PCR analysis  
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2.2.11 Transfection Methods 
Calcium Phosphate Transfection 
Within this project the calcium phosphate protocol was used for transient transfection of 
cells.  This protocol employs 2M Calcium Chloride (CaCl2) and 2 x HBS (50mM HEPES, 
280mM NaCl, 1.5mM Na2HPO4), that can be prepared before hand sterile filtered through a 
0.22μm filter and stored at -20°C. 
Day One: HepG2 were collected from a confluent flask (~70-75%), and seeded into the 
appropriate plate size depending on the experiment being performed.  The cells were then 
incubated overnight to allow the cells to adhere and establish within the plate.   
Day Two:  On the day of the transfection, 2M CaCl2 and 2 x HBS was removed from storage 
and allowed to completely thaw and come up to room temperature before use.  The cells 
being transfected were washed with warm 1 x PBS before fresh media was applied.     
The transfection mixes containing DNA/CaCl2/H2O was then added in a 1:1 ratio to   2 x 
HBS, and allowed to precipitate at room temperature for 30 minutes before being applied to 
the cells in a drop-wise manner.  The plates were then incubated between 16-18 hours, any 







2.2.12 Nuclear Receptor vectors used within gene analysis studies 
The HepG2 cell line model was transfected with expression vectors encoding human VDR, 
PXR, FXR and RXR alpha respectively.  The VDR, FXR and RXR constructs were created 
using the commercially available gateway compatible pcDNA/V5-DEST vector backbone.  
The pcDNA vectors are designed for high level, constitutive expression in a range of 
mammalian cell lines.  The pcDNA/V5 DEST vector contains Cytomegalovirus (CMV) 
immediate early promoter, which allows for efficient high level expression of recombinant 
protein; the presence of the c-terminal V5 epitope allowing for the detection of recombinant 
fusion proteins by anti V5 antibodies and the ampicillin resistance gene (Beta-lactmase), 
allows for the selection of transformants in E-coli.  
V5-hVDR and V5-hLXR had already been generated previously however in brief, from 
pSG5-hVDR that was also gifted by Professor Haussler the hVDR insert was amplified using 
PCR and cloned into the pDONER201 vector by BP clonase. This entry clone (pDONER201-
hVDR) was then employed in down stream gateway reactions using the vector pcDNA3.2 
V5-DEST vector facilitated via an LR clonase reaction, resulting in the generation of the V5-
hVDR construct.  A pDONER entry clone already existed for hFXR and therefore only 








2.2.13 Gateway cloning technologies 
A number of the constructs already existed within the laboratory (V5-hVDR,  
V5-hLXR), however the generation of the V5-hFXR was solely generated within this project.  
The schematic below highlights the steps involved in the generation of a gateway compatible 
V5 based construct.   
 
   
Vector map of the V5 DEST backbone used within this study 
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2.2.14 LR cloning reaction 
The LR reaction was carried out as described below. 
        Volume (μl) 
  - Entry clone (50ng)     1 
  - Destination vector (75ng)    1 
  - Gateway LR clonease II enzyme mix  1 
  - T.E. buffer pH 8.0     2 
  - Final Volume     5     
 
The above reaction mix was then allowed to incubate at room temperature for 2 hours, after 
which 1μl of protease K was added to cease the clonase reaction (2μg/ μl, provided with the 
clonase kit) and incubated at 37°C for 10 minutes.  The resulting expression vector was then 
transformed into library efficiency (LE) DH5α cells, detailed below), and colonies selected 
from Luria-Bertani (LB) agar plates (50μg/ml ampicillin), and grown in LB broth overnight.  
The plasmids subsequently underwent miniprep extraction using the Invitrogen Pure-Link™ 
Quick plasmid miniprep kit (Invitrogen, Cat: K2100-10).  To ensure the entry clone was 





















































Figure 2.1 Dose dependent expression of UGT1A genes in response to VDR 
and PXR ligands: LS180 cells were treated for 24hrs with vehicle control or 
indicated concentration of test ligand. Extracted RNA was reverse transcribed 
subjected to qRT-PCR analysis as per manufacturer’s protocol. Data are 
represented as means (± SEM) of three independent experiments, p<0.05 *, < 
0.01 **, and <0.001 ***. 




























Figure 2.2 Established VDR target genes exhibit dose dependent 
responsiveness:  LS180 cells were treated for 24hrs with vehicle control or 
indicated concentration of test ligand. Extracted RNA was reverse transcribed 
subjected to qRT-PCR analysis as per manufacturer’s protocol. Data are 
represented as means (± SEM) of three independent experiments, p<0.05 *, < 
0.01 **, and <0.001 ***. 
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2.3.1 UGT1A and known VDR target genes exhibit dose dependent responses 
qRT-PCR analysis was carried out to monitor transcriptional response of UGT1A family 
members within LS180 cells following exposure to varying concentrations of ligands for 
VDR and PXR.  Rifampicin was used as a PXR activator as this represents a known and 
established inducer of UGT1A activity (Mackenzie et al., 2003) allowing direct comparisons 
to those effects achieved through VDR. 
Figure 2.1 depicts the dose dependent nature UGT1A1 and UGT1A4 exhibit when exposed to 
natural and synthetic VDR ligands.  1,25(OH)2D3 at 1 and 10nM concentrations show a 
statistically significant induction of UGT1A1 and UGT1A4. EB1089 or Seocalcitol is a 
synthetic analogue of 1,25(OH)2D3 and does not have as strong an influence on calcium 
metabolism.  Within this experimental set up EB1089 at a 10nM concentration is showing 
over 6-fold induction of the endogenous UGT1A1 gene in LS180 cells with a three star 
significance vs. no statistical significance when compared to the PXR agonist Rifampicin at 
concentrations within the micro molar ranges.   
EB1089 has been utilized as an anti cancer agent as it has been seen to inhibit growth, induce 
differentiation and induce apoptosis of cancer cell line models in vitro (Evans et al., 2002), 
furthermore it has been used in the clinic trials as a treatment against hepatocellular cancer, 
witnessing complete remission of the cancer (Hansen et al., 2000).    
EB1089 induces target mRNA activity in LS180s giving an average induction of > 6 fold 
(UGT1A1) and >50 fold (UGT1A4) respectively.  This trend of heightened induction through 
the actions of EB1089 is very promising as it highlights the potential therapeutic application 
of EB1089 upon the regulation of key UGT1A members, as the same ability has been 
witnessed in a number if CYP450 members, (CYP3A4 and CYP3A5).      
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In addition to this the comparison between PXR and VDR with the understanding that PXR is 
a known prototypical inducer of UGTA activity shows a limited ability to induce mRNA 
production even at a micro molar level.  This is supported with the observations that 
statistically significant responses were seen at a nano molar level when LS180 cells were 
exposed to VDR agonists both natural and synthetic.     
Figure 2.2 depicts known VDR targets, including phase one genes (CYP3A4, CYP24A1) and 
calcium transporters (TRPV6).  As with the UGT1A members there is a definite dose 
dependent response seen amongst these genes.  CYP3A4 has a highly inducible response 
when exposed to EB1089 (~500 fold), as does TRPV6 (~100 fold) and CYP24A (~9 fold).  
Due to the high degree of variability and massive fold inductions witnessed upon CYP24A1, 











Figure 2.3 UGT1A members time course response within a 72hr time frame:  LS180 cells were treated with 
indicated concentration of test ligand before RNA extraction was carried out at each time point as detailed above. 
Extracted RNA was reverse transcribed subjected to qRT-PCR analysis as per manufacturer’s protocol. Data are 




Figure 2.4 Established VDR target genes; time course response within a 72hr time frame:  LS180 cells were treated with indicated 
concentration of test ligand before RNA extraction was carried out at each time point as detailed above. Extracted RNA was reverse 
transcribed subjected to qRT-PCR analysis as per manufacturer’s protocol. Data are represented as means (± SEM) of three independent 
experiments.      
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2.3.2 Time course analysis in LS180 model 
From the dose response study, appropriate concentrations of 1,25(OH)2D3, EB1089 and 
Rifampicin were chosen for time course analysis to be conducted.  10nM of 1,25(OH) 2D3 
was used as this concentration had previously been established with the laboratory and as is 
shown in the dose response gives clear statistical significance and reproducibility at this 
concentration.  Using 1nM EB1089 again shows statistically significant induction vs. vehicle 
control.  I also wanted to highlight even further the stark contrast in concentration of ligands 
to produce a significant transcriptional response, when PXR agonist Rifampicin is using 
concentrations in the micro molar ranges for less transcriptional responsiveness.  
The LS180 cell line model was used again to establish more fully the effects these agonists 
have on mRNA expression over a time period extending up to 72 hours.  Both UGT1A1 and 
UGT1A4 exhibit very similar trends in time course analysis. 1nM of EB1089 showing the 
most robust and prolonged transactivation of said targets, inducing mRNA levels of UGT1A1 
to > 10 fold and UGT1A4 to > 60 fold at 48 hours after which a sharp decrease in activation 
is seen at 72 hours. 1,25(OH)2D3 shows its peak being reached after 24 hours with a steady 
decline in activation thereafter.  The decline post 24 hours could be attributed to the rate at 
which the LS180 cells metabolize the natural agonist.  Rifampicin indicated a more 
progressive response reaching a peak at 48 hours where is levels off thereafter.  It is 
interesting to note that when the comparison between VDR and PXR activation is made, the 
PXR agonist rifampicin achieves similar levels of activation however the time required to 
reach this point is longer than 1,25(OH)2D3 .  1,25(OH)2D3  achieves its peak transcriptional 
response at 12 hours with Rifampicin achieving its peak transcriptional expression at 24 
hours. 
 85 
EB1089 shows again a super induction of CYP3A4, CYP24A1 and TRPV6, however 
CYP24A1 having such a potent ability to be induced through VDR activity does not show a 
decrease in responsiveness within the 72 hour window of the experimental procedure. 
CYP3A4 and TRPV6 share very similar trends when compared together.  CYP3A4 when 
exposed to both 1,25(OH)2D3 and EB1089 show a sharp increase in mRNA expression at 12 
hours.  At this point 1,25(OH)2D3 activity declines, most likely due to metabolic turnover of 
available ligand whereas EB1089s effectiveness is witnessed climbing at a steady rate to 48 
hours reaching an mRNA level of expression of approx. 600 fold.  The same trend is seen in 
TRPV6 with a fold induction of approx. 130 being witnessed at 48 hours when exposed to 
EB1089.   
CYP24A1 is one of the key metabolic genes involved in the turnover of physiologically active 
vitamin D.  Within the body a negative feedback loop is set up i.e. increase serum 
1,25(OH)2D3 results in a massive induction of CYP24A1.  The CYP24A1 graph is viewed as a 
ratio to HPRT due to the extreme variation in expression potential witnessed when ligand is 
introduced.   
The induction seen within UGT1A1 and A4 show less activation potential when compared to 
CYP3A4, CYP3A5 and TRPV6.  However the ability of VDR agonists to induce 
transcriptional responses across all genes analysed remains the greatest when compared to 
PXR mediated activation.  EB1089 shows potential promise as a therapeutic inducer of 
metabolic gene activity, however more research is required to establish the mechanism of 
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Figure 2.5 Bench Top PCR Analysis of UGT1A Family Members: Colon 
derived LS180 cells were treated with ligands for 24 hrs, the RNA extracted and 
PCR conducted using Go-Taq® Flexi DNA Polymerase.  Three independent 
experiments were performed and pooled for each treatment group.  HPRT has 
been used and the housekeeping gene with solvent controls for each treatment 
identified as Ethanol (ID1) and Methanol (ID4).   
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2.3.3 Bench Top PCR Analysis of UGT1A Family Members 
To assess UGT1A responsiveness, end point PCR was performed to allow a preliminary 
assessment of the potential action VDR agonists may have on endogenous levels of UGT1A 
expression in comparison to an established prototypical inducer PXR.  Figure 2.5 highlights 
the potential of VDR ligands to manipulate the expression of the UGT1A gene family in 
LS180 cells.     
  UGT1A1, A3, A4, A5 and A10 were shown to be regulated by VDR agonists all of which 
play varying but important roles within metabolism.  UGT1A1 as previously described is 
directly linked with a number of metabolic disorders, due to mutations being present in the 
UGT1A1 gene and or promoter.  All of the remaining members having varying roles in the 
detoxification of many lipophilic substrates including steroids, hormones and xenobiotics, 
within a wide variety of tissues throughout the body. 
There is a consistent pattern witnessed when exposed to VDR agonists.  EB1089 shows the 
most transcriptional responsiveness as is most evident in UGT1A1, UGT1A3 and UGT1A4.      
 It is interesting to note that the ability of VDR to regulate UGT1A members rivals that of 
PXR agonist Rifampicin.  All the UGT1A family members showed some degree of activation 
when exposed to VDR agonists.  Furthermore all the UGT1A members studied above showed 
transcriptional induction when exposed to the PXR agonist Rifampicin. 
  The above figure highlights the comparison between VDR and PXR, in their respective 
abilities to induce a transcriptional response.  PXR ligands are used currently in the clinic to 
induce expression of UGT1A1 an example of which is Irinotecan used in the treatment of 
colorectal cancer (Zhuo et al., 2014); therefore PXR remains a good benchmark from which 




























Figure 2.6 qRT-PCR Analysis of UGT1A Family Members: UGT1A 
expression profile elicited by VDR and PXR ligands. LS180 cells were treated 
for 24hrs with vehicle control or indicated concentration of test ligand. Extracted 
RNA was reverse transcribed subjected to qRT-PCR analysis as per 
manufacturer’s protocol. Data are represented as means (± SEM) of three 





























Figure 2.7 qRT-PCR Analysis of UGT1A Family Members continued: 
UGT1A expression profile elicited by VDR and PXR ligands. LS180 cells were 
treated for 24hrs with vehicle control or indicated concentration of test ligand. 
Extracted RNA was reverse transcribed subjected to qRT-PCR analysis as per 
manufacturer’s protocol. Data are represented as means (± SEM) of three 
independent experiments.  The UGT members detailed above showed no 
statistical significance.  
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2.3.4 Quantitative analysis of UGT1A members in the LS180 cell line model 
 
To detail further the ability of VDR to regulate UGT1A members, qRT-PCR analysis was 
performed on key members of the UGT1A family. UGT1A1, UGT1A3 and UGT1A4 were 
chosen to continue on as subjects in subsequent experiments.  These genes were chosen due 
to their clinical significance as well as their induction profiles witnessed through the dose 
response, time course and bench top PCR studies.  In addition to this UGT1A3 and UGT1A4 
have been implicated in an auto regulatory capacity within the vitamin D metabolic pathway 
(Wang et al., 2014b). 
 Transcriptional induction remains true when exposed to 1nM EB1089. This synthetic agonist 
has shown super inductive capabilities in a number of CYP450 members including CYP3A4 
and CYP24A1 (Doherty et al., 2014a).  A statistically significant induction does occur 
especially among UGT1A1, A3, A4 and A5 when exposed to both 1,25(OH)2D3 and EB1089, 
with fold inductions of UGT1A1 being seen at 4 and 5.5 fold respectively.  UGT1A3 and 4 
show profound mRNA induction with UGT1A3 showing at 8-fold change from control when 
exposed to E1089.  UGT1A4 indicates also a 40-fold change.  The ability of VDR agonists to 
induce UGT1A3 and UGT1A4 lends support to their role in vitamin D metabolism and 
clearance.  It does stand to reason that VDRE agonists would have the ability to induce 
expression of genes involved in agonist clearance to maintain homeostatic feedback 
mechanisms.    
Furthermore although similar trends were seen in other UGT1A members (1A7, A8, A10), 
there was not any statistical significance to report.   
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UGT1A1, A3 and A4 show a greater induction through the actions of endogenous VDR vs. 
that of PXR, indicating the prospect that VDR induction could be more beneficial than PXR 
agonists in eliciting a transcriptional response in colon.    
Due to the lack of statistical responsiveness seen UGT1A5, 7, 8 and 10 they were excluded 










































Figure 2.8 qRT-PCR Analysis of UGT1A Family Members vs. CYP3A4 in 
non transfected HepG2: UGT1A expression profile elicited by VDR, RXR & 
PXR ligands. HepG2 cells were treated for 24hrs with vehicle control or 
indicated concentration of test ligand. Extracted RNA was reverse transcribed 
subjected to qRT-PCR analysis as per manufacturer’s protocol. Data are 
represented as means (± SEM) of three independent experiments, p<0.05 *,       
< 0.01 **, and <0.001 ***. 





























Figure 2.9 qRT-PCR Analysis of UGT1A Family Members vs. CYP3A4 in 
nuclear receptor transfected HepG2:  UGT1A expression profile elicited by 
VDR, FXR & PXR ligands.  Each well was transfected using calcium phosphate 
methodology, with 2µg of V5-VDR, V5-FXR, or psg5-PXR respectively after 
which the cells were treated for 24hrs with vehicle control or indicated 
concentration of test ligand. Extracted RNA was reverse transcribed subjected to 
qRT-PCR analysis as per manufacturer’s protocol. Data are represented as 
means (± SEM) of three independent experiments, p<0.05 *,       < 0.01 **, and 
<0.001 ***. 
    
qRT-PCR analysis in transfected HepG2 
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2.3.5 Comparison of VDR and other related nuclear receptors to regulate UGT1A gene 
expression in a hepatic cell model  
The HepG2 cell line model was employed as a representative, hepatic cell line model 
allowing for the comparison between LS180 (colon), and HepG2 (liver) to be carried out.  
The liver remains the primary site for biological detoxification within the body and as such 
boasts the widest range of metabolic genes.  HepG2 cells do not express high levels of VDR; 
therefore the ability of VDR to regulate potential targets within the liver is limited.  This is 
consistent with literature in that VDR has limited expression in hepatic tissue.  Conversely 
PXR and a number other nuclear receptors are highly expressed throughout the liver 
(Lehmann et al., 1998b) and as such remain key regulators within the hepatic environment.  
HepG2 cells showed very little statistical induction of UGT1A members through invoking 
activation of endogenous VDR.  Furthermore the ability of Rifampicin to elicit a response 
through endogenous PXR was also lacking.  PXR however remains expressed at appropriate 
levels as induction was witnessed by the known PXR inducible gene CYP3A4 giving an 
mRNA fold induction of 2 fold (figure 2.9).   
The inclusion of bexarotene was considered, as RXR alpha (RXRα) is the heterodimeric 
partner that both VDR and PXR share to elicit their respective target responses.  It is 
interesting to see that bexarotene as an RXR alpha inducer has the ability to also induce 
UGT1A members, perhaps warranting further investigation, however this is beyond the scope 

















Figure 2.10 Absolute basal qRT-PCR Analysis of key UGT1A members vs. 
CYP3A4: The RNA was extracted from colon derived LS180 and hepatic 
HepG2 and RT-PCR conducted using SSRT (Invitrogen).  qRT-PCR analysis 
was performed on the LC480 Light Cycler.  Plotted is the relative target to 
housekeeper ratios across three independent experiments run in duplicate.     
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2.3.6 Basal qualitative analysis of UGT1A members in comparison to known VDR target 
gene CYP3A4 in the HepG2 and LS180 cell line models 
 
Figure 2.10 highlights the relative basal expression levels of each target gene (UGT1A1, 
UGT1A3, UGT1A4, and CYP3A4) in the absences of activating ligand.  This gives a sense of 
the expression levels relative to each of the cell lines being explored.   
It is evident that UGT1A members are expressed more highly in the enteric cell line model vs. 
the hepatic model. This adds additional credence to the rationale that extra hepatic expression 
of UGT1A members, controlled through VDR mediation could potentially play a vital role in 
overall detoxification and genome wide protection in additional tissues outside that of the 
liver.   
The reverse is seen in CYP3A4 basal expression, showing an increase basal expression in 
liver cells over the colonic model; however the ability of VDR to regulate CYP3A4 activity 
outside the liver has been documented through natural and synthetic vitamin D ligands 
















Figure 2.11 UGT1A1 is a direct Vitamin D/Vitamin D Receptor target:  LS180 cells were treated with VDR ligands 1,25D3 (10nM) 
and EB1089 (1nM) with (+) and minus (-) cyclohexamide (CHX).  The extracted RNA was reverse transcribed and subjected to qRT-
PCR analysis as per manufacturer’s protocol. Data are represented as means (± SEM) of two independent experiments with each data 
point run in triplicate.      
ns ns ns 
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2.3.7 UGT1A1 is a direct Vitamin D/Vitamin D Receptor target 
 
Cyclohexamide is a protein synthesis inhibitor by interfering with the translocation steps in 
protein synthesis blocking the elongation process in translation.   
Cyclohexamide was employed within this study to assess if VDR can regulate UGT1A 
members as a result of a direct transcriptional event and not through any secondary mode of 
regulation.  LS180 cells were treated with the concentration indicated in figure 2.11 with the 
addition of cyclohexamide or solvent control.   
There was no statistical significance noted with the addition of cyclohexamide.  EB1089 did 
not loss its ability to induce expression of UGT1A1, A4 or CYP3A4, giving mRNA level 
inductions comparable to the time course analysis at 24hrs, however it did seem to inhibit the 
previously witnessed ‘super induction’ of target genes.  Perhaps there is a tertiary interaction 
between ligand affinity being interrupted with the introduction of cyclohexamide that reduced 
the efficacy of EB1089?  This is an area that has potential for further investigation but is 
beyond the scope of this thesis.      
What can be concluded from the cyclohexamide study is that no tertiary protein is generated 
that could subsequently act on the promoter regions of the VDR targets eliciting a response.   
It is through direct VDR activity and not a secondary protein generation that UGT1A1, 


























Many studies have shown the role vitamin D and the vitamin D receptor have in targeting a 
number of metabolic genes within a range of disease states including prostate (Williamson et 
al., 2013), breast  (Fuady et al., 2016) and colon  cancers (Audet-Delage et al., 2017).  The 
finding that VDR can induce UGT1A expression in the LS180 cell line model further 
highlights the potential importance vitamin D and by extension, the vitamin D receptor in 
overall detoxification activity outside that of the hepatic environment.   
This chapter explores the expression of UGT1A gene family members in one colon cancer 
cell line as well as a liver cell line model (HepG2) allowing comparisons to be drawn.  
Defining further the potential role vitamin D and by extension the vitamin D receptor could 
have in overall regulation of these phase two metabolic genes. 
Microarray data has shown that VDR has the ability to induce phase two metabolic gene and 
stress response activity within the intestine as a result of the actions of 1,25(OH)2D3 
(Kutuzova and DeLuca, 2007), however this was the first study to explore VDR mediated 
activity of UGT1A genes, comparing the ability of VDR against other known and established 
inducers such as PXR.  The microarray analysis carried out by (Kutuzova and DeLuca, 2007) 
witnessed a 1.7 fold increase in expression levels of UGT1A members after 6 hours of 
exposure to agonist.  
It is also of great interest that the synthetic VDR ligand, EB1089, shows an ability to induce 
further UGT1A1, UGT1A3, and UGT1A4 to a greater extent than natural VDR agonist, 
1,25(OH)2D3 and Rifampicin, a PXR agonist.  EB1089 has been utilized within clinic trails as 
an anti cancer treatment (Hansen et al., 2000).  Furthermore EB1089 has been shown to be 
used as an anti proliferative agent in some colon cancers (Akhter et al., 1997).  EB1089 as a 
synthetic analogue of natural 1,25(OH)2D3 has all the properties of its natural counterpart 
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without the hypercalcaemia influences witnessed when increased natural 1,25(OH)2D3 is 
administered within the clinic.  Within the Thompson laboratory we have witnessed an 
increased transcriptional response of other VDR target genes including CYP3A4 and TRPV6 
when exposed to EB1089.  Witnessing a similar trend within the UGT1A family indicates that 
VDR could have the potential to regulate expression and activity.        
Furthermore the ability of VDR to induce a transcriptional response requires ligand 
concentrations at a nano molar (nM) level compared to a micro molar (µM) level when PXR 
agonist is used this could be caused by the confirmation of the nuclear receptor protein, 
requiring a higher concentration of ligand before the binding affinity threshold between 
ligand and receptor is reached due to the conformation of the ligand binding pockets 
(Mizwicki et al., 2004).  This in itself shows the greater affinity UGT1A members have 
towards VDR mediated activation over PXR stimulation.  
VDR agonists have the ability to elicit transcriptional responses at a nano molar level; this 
suggests that VDR activation of metabolic gene activity is a more deeply regulated process, 
maintaining a basal expression providing a homeostatic balance potentially generated basal 
genome protection through continual transcriptional signaling elicited through circulating 
VDR agonists at nano molar concentrations.   
All the UGT1A members explored within the study exhibited some degree of response to 
VDR mediated activation with UGT1A1, A3, A4 and A5 exhibiting the greatest responses. 
The ability of VDR to regulate UGT1A3 and UGT1A4 is of interest as glucuronidation of 
1,25D3 has been witnessed through the activity of both these UGT1A gene members (Wang 
et al., 2014c).  Furthermore the movement and transportation of vitamin D based glucuronide 
conjugates may contribute to the intestinal VDR responsive target genes including CYP24A1 
and TRPV6.  Thus the delivery of glucuronide conjugates through the biliary tract into the 
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proximal intestine has been shown to serve as a possible endocrine/paracrine signaling loop 
of VDR dependent gene expression and activity (Wang et al., 2014a).         
The real time analysis was carried out in LS180 and HepG2 cell lines, allowing for a direct 
comparison to be made between the ability of VDR to elicit a transcriptional response.  
HepG2 cells contain low endogenous levels of VDR and perhaps the concentration of ligand 
used in these experiments was not sufficient to elicit any statistically significant responses 
(Han and Chiang, 2009).  This allows us to examine the impact of exogenous VDR upon the 
expression of these genes in a cell line derived in a tissue of metabolic functioning.   
This in itself gives additional credence to the possible extra hepatic role VDR has in 
regulating UGT1A members, indicating that there may be tissue specific regulation of this 
gene family, however further investigation would be required to ascertain completely the 
tissue specific nature of the UGT1A gene family.   
Furthermore to ascertain that adequate levels of VDR and PXR were transfected, a western 
blot approach could have been used.  
Non-transfected HepG2 even when exposed to the PXR agonist Rifampicin, showed no 
statistically significant induction of UGT1A members. This was compared to CYP3A4 
highlighting the PXR response is present, indicating adequate levels of PXR being present to 
elicit certain target gene responses.  Attributing to this could be the basal expression levels of 
CYP3A4 vs. UGT1A members in the HepG2 cell line model.  CYP3A4 exhibits a higher basal 
expression over UGT1A members allowing for a greater activation potential to be achieved 
when exposed to agonist.     
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The lack of UGT1A activation could be due to the fact that HepG2 are a transformed cell line 
and perhaps primary hepatocytes would contain additional transcription factors that could 
enable a PXR mediated response of these phase two genes.   
Additionally when the comparison of basal levels of metabolic gene expression was 
ascertained between LS180 and HepG2 there was a distinctly lower level of expression in 
HepG2 as is seen in figure 2.10.  Basally, there is more expression of UGT1A members in 
colon vs. liver, conversely the expression of the phase one gene CYP3A4 was higher in 
HepG2 over LS180; the real time data supports this observation.  This finding highlighting 
basal expression between the LS180 and HepG2 cell line models, cements further, the 
potential extra hepatic role UGT1A members could play in overall body detoxification.  
Intestinal expression of key metabolic genes involved in detoxification as well as bile acid 
sensors have the ability to be regulated through the actions of VDR.  VDR has already been 
shown to be highly expressed within the intestine and as such has the potential regulate 
UGT1A genes within the intestinal environment.  Altered intestinal UGT expression resulting 
in increased glucuronidation activity has been shown to exacerbate bile acid injury within the 
colon (Zhou et al., 2014), indicating that nuclear receptors ability to regulate metabolic gene 
activity play vital roles in bile acid homeostasis and pathological development of colitis as 
well as other inflammatory based diseases of the intestine and colon, including IBD and 
Crohn’s Disease.   
Through the dose response and time course studies, we were able to observe the effect 
increasing concentration of both natural and synthetic ligands had on UGT1A1 and UGT1A4 
responsiveness in comparison to known VDR target genes.  Both UGT1A1 and 1A4 exhibit 
dose dependent responses, producing similar trend profiles.  UGT1A4 shows a greater 
induction over UGT1A1 eliciting approx. 20 fold induction when exposed to natural vitamin 
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D and 40-45-fold increase when challenged with EB1089.  Both family members showed 
stronger responses to VDR activation over PXR mediated activation   
In conclusion these results highlight the ability of VDR to elicit a transcriptional response to 
the same degree, if not more potently that known and established prototypical inducers such 
as PXR at a ligand concentration far lower than that of PXR agonists (nM vs. µM).  
Furthermore the lack of VDR expression in the liver indicates a more extra hepatic role vs. 
primary hepatic functionality.  This is further supported through the increased basal 










































Chapter 3: Identification and validation of a Vitamin D Response Element (VDRE) within 


























Nuclear receptors encompass a huge family of proteins that act as transcription factors 
binding lipophilic ligands ultimately mediating a transcriptional response of target genes, 
both activation and repression, through the recognition of specific stretches known as DNA 
response elements located within the promoter regions of gene.  These response elements are 
recognized through the actions of the DNA binding domain of the nuclear receptor.   
 Nuclear receptors 
Nuclear receptors belong to a super family of proteins and as such share closely related 
structures in their physical make up.  All nuclear receptors contain a ligand binding domain, 
and a DNA binding domain.  The DNA binding domain is comprised of a 66- residue 
conserved core and C terminal extension (Moras and Gronemeyer, 1998).  Furthermore the 
DNA binding domain contains eight highly conserved zinc fingers, the function of these zinc 
residues are to maintain the integrity of the binding domain allowing for the structure to hold 
fast.  DNA binding is achieved through the tetrahedral co-ordination zinc with four cysteine 
residues in two distinct extensions that form two structural “zinc fingers”.  Zinc fingers are 
common among gene regulatory proteins and the specificity of hormone response elements is 
achieved through the more conserved hydrophilic first zinc finger (C1), whereas the 2nd zinc 
finger is involved in dimerization and stabilizing the DNA binding through interactions with 
the DNA phosphate backbone.  The removal of the zinc molecules from the DNA binding 
domain leads to the complete unfolding of the DNA binding domain, resulting in an inability 





The C1 zinc finger interacts directly with five base pairs of DNA determining the DNA 
sequence to be recognized by particular steroid nuclear receptors.  The three orange amino 
acids highlighted above indicate the P-box region within the C1 motif.  The shaded amino 
acids on the right indicate the D-box, involved in dimerization and contacts with the DNA 










Illustration 3.2: 1 dimensional representation of nuclear receptor structure.   
Illustration 3.1: Schematic showing zinc finger protein characteristics within 
the DBD structure of steroid hormone nuclear receptor family members.  
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The promoter: DNA response elements 
 
The transcription of DNA to messenger RNA is one of the most important processes 
controlled by steroid nuclear receptors.  All genes within the body share a common basic 
structure and design.  Structural regions include stretches of DNA that encode for specific 
amino acids, and a regulatory region that interacts with various proteins that control the 
overall rate and transcription.  Within these regulatory regions several key elements must be 
present before transcriptional activation can occur.  These elements are known as cis-acting 
elements, and are located near the 5’ end of the gene, and consist of four main groups; 1) 
promoters, 2) hormone response enhancers 3) silencers and 4) hormone independent 
enhancers. 
The promoter of a gene is located closest to the transcriptional start site.  DNA that nuclear 
receptors recognize and bind to are known as DNA response elements (REs), and can be 
found both preceding and after the gene the element has a transcriptional effect on.  The 
recognition and binding of response elements can be achieved through homo and 
heterodimeric interactions.  There are a number of nuclear receptors that act as monomers, 
principally nuclear receptor subfamily 2 (Khorasanizadeh and Rastinejad, 2001). 
 
Depending on which DNA binding mofit is targeted during nuclear receptor activation, will 
determine if the target gene is trans activated or repressed.  The RAR/RXR heterodimer can 
elicit both outcomes (Aranda and Pascual, 2001a).  Binding of a direct repeat separated with 
one nucleotide results in repression of transcription whereas the binding to a direct repeat 
separated by five nucleotides results in activation of the target gene.   
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There are a range of motifs that have extremely potent effects as a result of nuclear receptor 
binding.  Direct repeats and everted repeats both remain highly effective at eliciting 







 Vitamin D response elements 
 
Many of the genes that respond to the actions of the Vitamin D Receptor (VDR) contain 
within their promoter region direct repeat response elements separated by three nucleotide 
spacers (DR3) or everted repeats separated by six spacer nucleotides (ER6).  VDR forms a 
heterodimeric complex with RXR alpha and forms said complex in a 5’-RXR/VDR-3’ 
polarity where RXR occupies the upstream half site and VDR occupies the down remaining 
down stream half site (Schräder et al., 1995).  VDR has been seen to act as a homodimer 
however little effect is seen and is therefore thought not to play a major role in transcriptional 
control (Cheskis and Freedman, 1994).  
 
 
Illustration 3.3: Hormone response elements found within human 














The homology shared between the nuclear receptors indicates toward the potential for 
crosstalk between each of the receptors members.  As such the pregnane X receptor (PXR) 
has the ability to bind to a number of response elements such as the DR3 and ER6 motifs, 
highlighting potential for competitive binding to occur between the two receptors.  This 
homology between PXR and VDR highlights the intriguing potential for VDR to regulate 
detoxification genes as PXR has been established as the master regulator of many metabolic 





Illustration 3.4: Schematic highlighting the DR3 configuration within 
potential VDR targeted genes.  
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Chapter Rationale  
Within this chapter VDR ligands were shown to have the ability to induce the phase two 
metabolic gene UGT1A1.  To further characterize the induction profiles; comparison between 
known and established inducers of the UGT1A1 gene promoter were used to ascertain a base 
line from which to compare the ability of VDR to induce UGT1A1 at a transcriptional level.  
This was achieved through bioinformatic analysis ascertain the presence and precise location 
of any classical vitamin D response elements (VDRE) within the promoter enhancer module 
of the UGT1A1 gene.  Two promoter constructs were kindly gifted to our lab by Professor 
Masahiko Negishi (North Carolina, USA). One construct containing a 2 kilobase fragment of 
the UGT1A1 promoter beginning from the start site of the promoter to include an enhancer 
region previously described by (Tukey et al., 2001).  This enhancer module contains various 
response elements for a number of nuclear receptors previously reported.  The second 
promoter vector contained only the 290bp enhancer module as described above.  Both these 
constructs were created using the pGL3 basic backbone, commercially available through 
Promega.  The human embryonic kidney cell or HEK-293 cell line and HepG2, previously 
described, was used throughout these experimental procedures.   HEK-293 model has been 
well established and characterized.  It is an easily transfectable cell line model and can be 
used as a ‘blank’ host for transfection/luciferase studies.  Luciferase reporter assays were 
performed initially comparing both constructs to determine which vector responded better or 
potential VDRE motifs.  This would allow us to focus primarily on a single vector construct 
moving forward.  Luciferase activity was then coupled with mutagenesis reactions to assess 
identified motifs for their specificity and requirement for intact sequences for mediating a 






























3.2.1 Cell Culture 
 
HEK-293 cells were maintained in Minimum Essential Media (MEM), 10% foetal bovine 
serum and 1% penicillin/streptomycin (Gibco, Paisley, UK) and kept at 37°C, 5% CO2 and 
95% air.  Trypsin disassociation was employed as previously described in materials and 
methods, chapter 2.   
3.2.2 Vectors used in study 
Both the pGL3-UGT1A1-U2K, and pGL3-UGT1A1-290 were kindly provided by Professor 
Masahiko Negishi, Research Triangle Park, North Carolina. 
The various nuclear receptors such as VDR-V5, FXR-V5, LXR-V5, PXR-psg5, RXR-psg5 
were all generated in house using the V5 or psg5 backbone allowing for the V5 epitope to be 
identified later on using western blot technologies.  The process of generating these 
constructs is detailed in section 2.16 and 2.17.      
3.2.3 Luciferase activity assay in HEK-293 to measure VDR, FXR, PXR, LXR (V5)-
RXR (psg5) mediated transcriptional activity using Calcium Phosphate transfection 
24 well plate set up 
Day One: 1x105 cells were seeded in each well of a 24 well plate, 500μl final volume. 
Day Two: Cells were transfected with 350ng, of reporter vectors, UGT1A1-290bp, or 500ng 
UGT1A1-U2K respectively, 100ng of V5-VDR, V5-FXR, V5-LXR, and 100ng psg5-RXR 
were also added; assay dependent.  The total amount of DNA was kept constant using empty 
pgl3-basic vector (up to 1μg).   
 114 
Day Three: Cells were washed with 1 x PBS and treated with the appropriate ligand and 
complete media mix for 24 hours. 
Day Four: The cells were lysed in 150μl of 1 x reporter lysis buffer and placed in  
a -20°C freezer to undergo a freeze thaw cycle, and subsequently placed on a moving 
platform for 45 minutes to ensure complete cell lysis.  20μl of the cell lysate was then loaded 
into an opaque 96 well plate.  To each well 50μl of luciferase substrate (LARII), (Promega, 
Madison, USA) was added and luminescence was recorded using the FLUOstar Omega 
micro plate reader.  The raw luciferase numbers were then normalised to total protein 
concentration as described previously.      
3.2.4 Calcium Phosphate Transfection 
Within this set of experiments the calcium phosphate methodology was used as the system 
had been previously optimized within the laboratory.  This protocol employs 2M Calcium 
Chloride (CaCl2) and 2 x HBS (50mM HEPES, 280mM NaCl, 1.5mM Na2HPO4), that can be 
prepared before hand sterile filtered through a 0.22μm filter and stored at -20°C. 
Day One: HepG2 or HEK-293 were collected from a confluent flask (~70-75%), and seeded 
into the appropriate plate size depending on the experiment being performed.  The cells were 
then incubated overnight to allow the cells to adhere and establish within the plate.   
Day Two:  On the day of the transfection, 2M CaCl2 and 2 x HBS was removed from storage 
and allowed to completely thaw and come up to room temperature before use.  The cells 
being transfected were washed with warm 1 x PBS before fresh media was applied.     
The transfection mixes containing DNA/CaCl2/H2O was then added in a 1:1 ratio to   2 x 
HBS, and allowed to precipitate at room temperature for 30 minutes before being applied to 
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the cells in a drop-wise manner.  The plates were then incubated between 16-18 hours, any 
longer than this and cell death can occur.   
 
3.2.5 Site-directed mutagenesis reactions 
Mutant primer design 
All mutant primers were designed using the online Agilent Quick Change Mutant Primer 
design software.  The online system uses built in parameters to generate optimum mutant 
primers for the input sequence provided.  The mutagenesis PCR was used to create two base 
pair changes within a postulated VDRE located in the enhancer module of the UGT1A1 gene 
promoter vector.  The base change from Wild Type to mutant is detailed further in the results 
section of this chapter.    
 
Mutant primers used within mutagenesis reactions 
Primer Name 5’ to 3’ Sequence 







Site-directed mutagenesis reaction 
Two point mutations were introduced using the Agilent Quick Change site-directed 
mutagenesis kit (Agilent Technologies, Texas, Cat: 200519-5).  The recipe below was used 
for the PCR amplification using reagents in the kit provided.  
  
   Volume (μl) 
- 10 x Reaction buffer  5 
- Forward Primer (125ng)  x 
- Reverse Primer (125ng)  x 
- Template (50ng/μl)  1 
- dNTP mix    1 
- PCR grade H2O   up to 50μl 
- Pfu Turbo enzyme  1 
 
After all the reagents were added to the PCR tube the reaction mix was briefly spun before 















The extension time is determined by the length of the template being mutated i.e. 1 minute 
for every 1 kilobase of template.  Upon completion of the amplification process 1μl of Dpn I 
restriction enzyme was added and incubated at 37°C for 1 hour.  Once the digestion was 
complete, standard transformation protocol was followed to transform 1μl of the PCR mix 
into library competent DH5α cells using S.O.C. broth as recovery media. Minipreps were 
then made and confirmation of the mutant carried out via restriction digest and DNA 
sequencing as detailed above.  Upon confirmation of mutated plasmid the miniprep was re-






Initial Denaturation 30 seconds, 95°C 
Denature  
12 cycles 
30 seconds, 95°C 
Annealing 1 minute, 55°C 
Extension 5 minutes, 68°C 
Final Extension Disabled  
Hold 4°C 
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3.2.6 Whole Cell Protein Extraction 
Transfected cells had media removed and washed in 37°C, 1 x PBS.  1ml of trypsin was then 
added to the plates and allowed to incubate for 5 minutes.  2mls of complete media was then 
added to neutralize the trypsin.  The plates were washed to ensure complete removal of all 
cells into suspension, before being collected and spun at 2000 rpm in a universal.  The 
resulting pellet was then washed in ice-cold 1 x PBS, before being spun at 2000 rpm 
reforming the cell pellet.  The supernatant was then removed and the cell pellet resuspended 
in ~100-200μl of RIPA buffer (25mM Tris-HCl; pH 7.8, 150mM NaCl, 1mM EDTA; pH 8.0, 
0.5% Igepal CA-630, 0.5% Sodium Deoxycholate, 0.1% SDS, 1mM DTT, 10% glycerol, and 
protease inhibitor cocktail), (Sigma), depending on the size of the cell pellet being 
resuspended.  The lysis mixture was then maintained on ice for 30 minutes, with agitation 
every 10 minutes to ensure complete lysis of the cells.  The lysis mixture was then spun at 
12,000 rpm for 10 minutes at 4°C.  The resulting supernatant was collected and stored at -
80°C for future use.  
 
3.2.7 Bio-Rad DC protein assay 
The total protein yield from whole cell lysate extractions and reporter lysis buffer extractions 
were quantified using the Bio-Rad DC protein assay (Cat: 500-0116).  Protein standard 
bovine serum albumin (BSA) was requisitioned from Sigma at a stock concentration of 
2mg/ml and underwent a 2 fold serial dilution using 1 x PBS when the assay was being 
performed.  The protein assay was performed in a tissue culture grade 96-welled plate, and 
standards were generated to a final volume of 10μl.   
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Whole cell lysate:  These samples were thawed on ice and diluted 2μl of lysate in 8μl of 1 x 
PBS (1:5 dilution factor), creating a final volume of 10μl.  
Reporter buffer lysis:  A 10μl aliquot of lysate was loaded directly into a 96-welled plate.  
To the 10μl standards and samples 25μl of A’ was added. A’: prepared by adding 20μl of 
reagent S (Bio-Rad Cat: 500-0115), and 1ml of reagent A (Bio-Rad Cat: 500-0113).  This 
was then immediately followed by the addition of 200μl of reagent B to each well (Bio-Rad 
Cat: 500-0114).  The plate was then allowed to incubate at room temperature for 15 minutes 
and the absorbance read at a wavelength 750nm using FLUOstar Omega microplate reader.  
All protein concentrations are calculated against the standards using the formula protein conc. 













3.2.8 Western blot analysis 
Over expression of V5-based constructs were detected by western blot, using home made 
gradient gels (4-10%), and the Bio-Rad Trans-Blot semi dry transfer cell.  30-50μg of lysate 
was loaded along with LDS, reducing agent, and RIPA, as per laboratory protocol. 
       Volume (μl) 
 - Cell lysate (30-50μg)    x 
 - NuPAGE LDS sample buffer (4x)   5 
 - NUPAGE Reducing Agent (10x)   2 
 - RIPA Buffer      made up to 20μl 
Each sample along with any blanks were heated to 95°C for 5 minutes before being loaded 
into the wells of the gradient western gel.  5μl of Spectra™ Multicolour Broad Range Protein 
Ladder (Fermentas) was loaded into well number 1.  The gel was run in SDS PAGE western 
blot running buffer (recipes highlighted below).  The gel was run at 80 volts for 10 minutes to 
allow entry of the protein into the 4% stacking gel, before switching to 150 volts for 1 hour.  
After the electrophoresis had run, the gel was placed on the semi dry transfer cell to transfer 
the resolved proteins onto a nitrocellulose membrane (Amersham Biosciences).  The transfer 
cell was run at 20 volts for 1 hour.  To ensure complete transfer of proteins to the membrane 
was stained with Ponceau S solution (Sigma Cat: L7170).  The stain was then removed by 
agitated washing in TBS-T (Tris Buffered Saline and Tween-20), this was followed by a 5% 
block using a milk powder solution (Marvel), made up using 1 x TBS-T, for 1 hour at room 
temperature.  The blocked membrane was then washed in 1 x TBS-T for 10 minutes to 
remove any excess blocking solution before being placed in TBS-T containing primary 
antibody for overnight incubation and 4°C.  The following day the membranes were washed 
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3 times for 10 minutes in 1 x TBS-T to remove any unbound primary antibody.  Once the 
final wash was complete the membranes were incubated with secondary antibodies 
conjugated with horseradish peroxidase in 1 x TBS-T for 1 hour at room temperature.  This 
was then followed by another 3 washes in 1 x TBS-T each of 5 minutes.  The membranes 
were then incubated for 5 minutes with Millipore Immobilon Western Chemiluminescent 
HRP substrate (Millipore; WBKLS0100) containing equal volumes of luminol solution and 
peroxide buffer; 500μl of each was sufficient.  The luminescent signal was then detected 
using the Sygene G:BOX Chemi system.   
 
Antibodies and their dilutions used in Western blot analysis 
Primary Antibody Secondary Antibody 
Mouse anti V5 (Invitrogen, Cat: 46-
0705) 
1:5000 Rabbit anti Mouse (Serotec, 
STAR13B) 
1:3000 
Rabbit anti HPRT (Serotec Cat: sc-
20975) 








Western blot reagents 







Make up to 1000ml using dH2O and store at room temperature 







Make up to 2000ml using dH2O and store at room temperature  





Add 800ml of dH2O and pH to 7.5 using conc. HCl, make up to 1000ml post pH. 
1 x TBS-T 








3.2.9 Mammalian-1-Hybrid/GAL4 based Transcription Assay 
Principle 
The mammalian-1-hybrid is an artificial system used to measure protein-DNA interactions.  
In this system the detection is based on the interaction of a single protein (known as the prey) 
with a bait DNA sequence position up stream of a reporter gene.  The prey protein is fused to 
a transcriptional activation domain; therefore positive protein DNA interactions bring the 
fusion activation domain into close proximity with the promoter element resulting in 
activating down stream transcription of the report gene as illustrated below. 
The mammalian-1-hybrid assay was conducted in HEK-293 cells and includes the ligand-
binding domain of nuclear receptors (VDR, RXR, FXR) fused to the DNA binding domain 
(DBD) of the GAL4 construct.  When the nuclear receptor binds the DBD, and LBD come 
into close proximity eliciting a transcriptional response.  This response can be read through 
luciferase activity.  The Thompson laboratory remains the only one to employ such 
technologies to determine ligand affinity for a given nuclear receptor. 
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Figure 3.1 UGT1A1-290bp-pGL3 basic construct: (A) Schematic detailing the 
commercially available pGL3-basic vector (Promega). (B) Indicates the enhancer 




3.3.1 UGT1A1-290bp-pGL3 basic construct 
The UGT1A1-pGL3 basic constructs are artificially engineered vector constructs with 
endogenous promoters or sections of promoter regions ligated into the backbone of the 
pGL3basic vector that is commercially available from Promega.  The two UGT1A1 
constructs used within this study contained 2kb (U2K) fragment while the other contained a 
290bp enhancer module, (detailed in figure 3.1).  Both the pGL3-UGT1A1-U2K, and pGL3-
UGT1A1-290 were kindly provided by Professor Masahiko Negishi, Research Triangle Park, 
North Carolina.  Figure 3.1 details within the 290bp stretch of promoter lies a number of 
nuclear receptor response elements.  It was due to this presence that the 290bp fragment 
became the focus of this research study, as the U2K construct, although containing more 
promoter than the smaller construct showed negligible difference in expression profiles when 





















































Figure 3.2 Schematic of the UGT1A1 gene promoter:  (A) highlights known and established inducers of the UGT1A1 
gene. (B) Indicated using the red circle shows the previously unknown VDRE element within the 290bp enhancer module, 
located distal to the start site.     
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3.3.2 Schematic of the UGT1A1 gene promoter 
Figure 3.2 details a schematic of the UGT1A1 promoter beginning at the start site of the gene 
where there is an HNF1alpha binding site that is thought to be key requirement for the 
expression and activity of UGT1A1 within the liver.  The diagram further details the presence 
of CAR, PPAR, AhR and PXR binding sites within the 290bp module located 3.2kb upstream 
of the start.  The elements highlighted in red indicate the previously unidentified VDRE.  
This being said Tukey, et al had previously explored the motif in question and identified it as 
an SXRE or PXRE. To date this motif has not been explored in its capacity to be a Vitamin D 




















Figure 3.3 Preliminary luciferase report vector titrations:  HEK-293 cells were transfected using calcium phosphate 
methodology with the above amounts of reporter vector (pGL3-basic) and nuclear receptor constructs (V5-VDR, psg5-
RXR).  The cells were then treated for 24hrs with 10nM 1,25(OH)2D3, after which a single glo luciferase assay was 
performed as per manufactures protocol, standardising to total protein concentration.  The above preliminary 


















Figure 3.4 Preliminary luciferase activities, defining nuclear receptor effects on the UGT1A1 promoter:  HEK-293 cells 
were seeded at a density of 1x105 cells/well and transfected using the calcium phosphate methodology with the indicated reporter 
(UGT1A1-290bp, 350ng, 2000bp, 500ng) and nuclear receptor (100ng) construct. The cells were treated for 24hrs with 10nM 
1,25(OH)2D3  1nM EB1089, 1µM GW474064A & 20µM Rifampicin, after which a single glo luciferase assay was performed as 
per manufactures protocol, standardising to total protein concentration.  The above preliminary experiments were ran as n=1 with 
each data point run in triplicate.    







Figure 3.5 Preliminary luciferase, coupled with V5 and gfp western activity:  HEK-293 cells were seeded at a density of 1x105 
cells/well and transfected using the calcium phosphate methodology each receiving 100ng of nuclear receptor vector as detailed above 
(gfp or V5-VDR, FXR, or psg5-RXR). The cells were treated for 24hrs with 10nM 1,25(OH)2D3  or 1µM GW4704064A followed by 
a single glo luciferase assay being performed as per manufactures protocol, standardising to total protein concentration. Whole protein  
lysates were extracted from 100mm dishes seeded at 8x105 and transfected with 1µg of each construct, with no treatment.  The protein 
was quantified using Bio Rad technology and 50µg of lysate was loaded on a 4-12% polyacrylamide gel.      
 132 
3.3.3 Preliminary luciferase studies 
Preliminary luciferase studies were carried out to ascertain the appropriate amount of each of 
the reporter vectors and nuclear receptor vectors to be used in later experiments.  As can be 
seen from figure 3.3 HEK-293 cells were used to establish vector concentrations required for 
optimal luciferase read outs.  Section A of figure 3.3 represents a constant amount of the 
UGT1A1-290bp vector construct with varying amounts of nuclear receptor constructs 
VDR/RXR.  The 2nd graph in section A details a constant amount of nuclear receptor 
construct (100ng of VDR and RXR respectively), with varying amounts of UGT1A1-290bp 
pGL3 basic construct.  The 2nd graph shows a drop in luciferase activity when greater than 
400ng of vector was added.  This loss of luciferase activity could be down to a lack of 
transfection efficiency due the higher amount of vector being added to the cell models.  
Section B of figure 3.3 depicts the same format as previously described however it utilized 
the larger UGT1A1-U2K construct instead.   
It was determined 350ng of the UGT1A1-290bp construct was adequate.  500ng of the U2K 
fragment was also deemed acceptable.  Each of the preliminary studies was carried out using 
10nM 1,25(OH)2D3 as the agonist.   
Figure 3.4 A utilizes the UGT1A1-290bp construct and is used to establish the activation 
profiles varying nuclear receptors have in the enhancer motif housed within the pGL3 basic 
construct.  The first graph within 3.4 A; represents the relative luciferase values whereas the 
2nd graph has been calculated to express the fold change, standardising the measurements to 
each of the respective vehicle controls.  FXR was used within this experimental set, as a 
potential avenue for investigation through FXRs endogenous role in bile acid sensing and 
downstream metabolic regulator.  These experiments where conducted as preliminary trials 
and as such only performed once with three technical repeats within each data set.  As with 
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figure set 3.3B, 3.4B represents the same set up as described above only employing the larger 
UGT1A1-U2K vector construct.  From these preliminary experiments, it was decided to focus 
soley on the 290bp fragment in later experiments, as the larger U2K fragments did not yield 
any greater luciferase activity when comparing fold change between both the UGT1A1 
constructs.       
After witnessing the luciferase activity within figure 3.3 when the UGT1A1 enhancer module 
was exposed to FXR agonist GW4704064A we decided to explore this slightly further 
resulting in a direct comparison between FXR and VDR activity.  Originally the V5 
constructs for both VDR and FXR were used however only VDR-V5 was detectable via 
western blot analysis as is shown in figure 3.5.  Psg5-RXR was used as an internal control to 
ascertain anti-V5 specificity when probing the cellulose membrane.  The V5 epitope may 
perhaps be hidden amongst the confirmation arrangement of the FXR protein restricting the 
ability of the V5 antibody to bind, making it undetectable via western blot.  This resulted in 
the use of a gfp-based construct being attempted, utilizing gfp-VDR and gfp-FXR.  Again 
FXR was undetectable.  At a luciferase level, however the presence of FXR does elicit a 
response in activity on the UGT1A1 promoter in comparison to no nuclear receptor being 



















Figure 3.6 Comparative nuclear receptor activity of the UGT1A1 (290bp (A) & 2000bp (U2K) (B)) promoter in 
HEK-293 cells: HEK-293 cells were seeded at a density of 1x105 cells/well and transfected using the calcium phosphate 
methodology with the indicated reporter (UGT1A1-290bp, 350ng, 2000bp, 500ng) and either empty vector or 100ng of 
each  nuclear receptor construct keeping DNA amounts constant.  The cells were then treated for 24hrs with 10nM 1,25D3, 
1µM GW4704064A or 20µM Rifampicin, after which a single glo luciferase assay was performed as per manufactures 
protocol, standardising to total protein concentration.  Data are represented as means (± SEM) of two independent 













Figure 3.7 Comparative nuclear receptor activity of the UGT1A1 (290bp (A) & 2000bp (U2K)(B)) promoter in 
HepG2 cells: HepG2 cells were seeded at a density of 1x105 cells/well and transfected using the calcium phosphate 
methodology with the indicated reporter (UGT1A1-290bp, 350ng, 2000bp, 500ng) and either no nuclear receptor or 100ng 
of each construct.  The cells were then treated for 24hrs with 10nM 1,25D3, 1µM GW4704064A or 20µM Rifampicin, 
after which a single glo luciferase assay was performed as per manufactures protocol, standardising to total protein 
concentration.  Data are represented as means (± SEM) of two independent experiments, with each data point performed in 





3.3.4 Comparative nuclear receptor activity of the UGT1A1 (290bp & 2000bp (U2K)) 
promoter in HEK-293 vs. HepG2 cells 
 
 
Figure 3.6 was carried out using the HEK-293 cell model transfecting each with a nuclear 
receptor construct comparing directly VDR activity against PXR and FXR.  The upper panel 
of figure 3.6 utilizes the 290bp UGT1A1 construct whereas the lower panel used the larger 
U2K fragment.  Each well was then treated with their respective agonist as detailed in figure 
legend 3.6 for a period of 24 hours before luciferase activity was measured.   
 
The comparison between VDR and PXR activation is of great interest as we hypothesized 
that VDR and PXR share the same binding motif, and that competitive binding may occur 
between the nuclear receptor constructs.  With this in mind VDR seems to have preference 
over PXR, as is indicated through an almost 3.5 fold induction compared to a non-significant 
induction mediated through PXR.   
 
FXR again shows a modest activation of the UGT1A1 promoter and further investigation into 
its relationship amongst the other nuclear receptors should be pursued, however remains 
beyond the scope of this project.     
 
The 2nd panel of graphs shows an identical set up as before only using the UGT1A1-U2K 
promoter vector.  Very similar expression profiles are seen when the larger construct is used 
vs. the smaller 290bp construct.     
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Figure 3.7 uses the same experimental set up as described previous, however the cell model 
used is the HepG2 cell line.  Within this data set the PXR response was seen when the PXR 
agonist Rifampicin was added.  This is in direct contrast with the same experimental set up 
only using HEK-293.  This in itself could indicate tissue specificity, perhaps eluding to the 
presence of addition transcription factors present in liver derived cells that may not be present 
in other cell models?  Furthermore the VDR activation potential remains present in the 
HepG2 model even though PXR activation is also present.  The FXR response is present, but 



















Figure 3.8 Mammalian One Hybrid, indicating ligand/receptor specificity in the HEK-293 cell line: HEK-293 cells 
were seeded @ 1x105 cells/well and transfected with 640ng pFR-Luc, 30ng phRL-TK and 100ng of pCMV BD/NRLBD 
(VDR, FXR or RXR).  The cells were then treated with the above ligands for 24hrs before dual glo luciferase readings 
were taken. Data are represented as means (± SEM) of three independent experiments, with each data point performed in 
triplicate (n=3) p<0.05 *, < 0.01 **, and <0.001 ***.   
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3.3.5 Mammalian One Hybrid, indicating ligand/receptor specificity in the HEK-293 
cell line 
The Thompson laboratory remains the only one to utilize the mammalian one hybrid 
technology within the UK.  This assay was designed to determine the affinity of different 
ligands towards nuclear receptor ligand binding domains (LBDs).  The assay employs the 
GAL4 DNA binding domain fused to the nuclear receptor ligand-binding domain.  Upon 
ligand binding/interaction the GAL4 DNA binding domain would bind to the GAL4 DNA 
response elements on the phFR-Luciferase promoter resulting in a transcriptional and 
therefore luciferase based response.  It was used to ensure that all the ligands used within the 
study where indeed specific agonists to their respective nuclear receptors. 
HEK-293 cells were transfected with vectors containing the nuclear receptor ligand binding 
domains for VDR, FXR and RXR.  These were then treated with natural (1,25(OH)2D3), 
primary/secondary bile acids) and synthetic (Bexarotene and GW474064A) agonists.   
Figure 3.8 shows that secondary bile acids are agonists for both FXR and VDR, inducing 
both VDR and FXR activity in HEK-293 cells.  Secondary bile acids however have an even 
more potent effect on VDR binding.  Indicating perhaps the potential for VDR to be activated 
in a tissue specific manner as previous studies conducted within the laboratory detailed a lack 
of primary bile acids to induce VDR in Caco-2 cell model.
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 5’- ggttcataaagggta - 3’ 
Wild Type 
5’ - ggttcataaaTAgta - 3’ 
Mutation 
Mutant VDR vs. PXR Mutant VDR vs. FXR Wild type VDR vs. Mutant 
Figure 3.9 UGT1A1 290bp Wild Type vs. VDRE mutant construct: HEK-293 cells were seeded @ 1x105 cells/well and 
transfected with constructs harbouring intact or mutated versions of the putative VDRE sequence/pGL3-UGT1A1-290bp 
(350ng) and indicated receptor reporter vectors (100ng each) respectively.  All transfected cells were then treated for 24 
hours with VDR, PXR and FXR ligands, detailed above.  Data are represented as means (± SEM) of two independent 




3.3.6 UGT1A1 290bp Wild Type vs. VDRE mutant construct 
The mutant UGT1A1 construct was created using the UGT1A1-290bp-pGL3 and specifically 
designed mutant primers created through the Agilent Technologies online primer design 
software.  Figure 3.9 highlights the nucleotide change to create the mutant VDRE motif.  The 
orientation of the mutation will was chosen as it will inhibit the binding of VDR to the VDRE 
motif as the heterodimer complex formed between VDR and RXR lies binds with the 
orientation as RXR:VDR (5’ to 3’).  
As a result of the mutation VDR could no longer bind resulting in a loss of luciferase activity 
as is evidenced through figure 3.9.  By using the synthetic analogue of vitamin D, EB1089, 
we can see the drastic loss in activity, in comparison the with Wild Type construct.  
Furthermore there is an additional loss of activity surrounding PXR binding adding additional 
credence to the hypothesis that the two nuclear receptors, VDR and PXR share the same 
binding motif within the enhancer module.  The final graph details the wild type construct vs. 
the mutant construct against various VDR agonists, natural, synthetic and bile acid derived.  














This chapter was used to identify, test and validate the putative VDRE located within 
the enhancer module of the UGT1A1 promoter, to ascertain how ligands specific to 
VDR were inducing the gene at an mRNA level discussed in chapter three.  Within 
this chapter luciferase based assays were optimized using two major cell in an attempt 
to compare the relative expressive abilities of the UGT1A1 in two different tissue 
types.  The VDRE being targeted within this chapter has the orientation known as a 
direct repeat or DR3 motif, which has previously been identified as a PXRE binding 
motif (Chen et al., 2012), however no one has identified the same binding site as a 
motif for the Vitamin D receptor.  The homology shared between both PXR and VDR 
makes its very likely that they too would have the ability to competitively bind the 
same and similar DNA motifs with a given gene promoter (Laudet et al., 1992). 
The luciferase technologies were used to assess how potent an induction 
1,25(OH)2D3, and EB1089, as VDR agonists, Rifampicin as a PXR agonist, and 
GW474064A as an FXR agonist were upon the expression of the UGT1A1 promoter, 
while also allowing for a comparison to be made between agonists as PXR and FXR 
are already established prototypical inducers of the endogenous UGT1A1 gene (Guo 
et al., 2003). 
The luciferase technology used within this study has previously been established 
within the laboratory however the amount of promoter vector and nuclear receptor 
constructs were unknown at the time.  Throughout this study the single glo luciferase 
assay was used, normalizing the absolute luciferase values to overall protein 
concentration using the Bio-Rad DC protein assay.   
 144 
 VDR has been shown to bind DR3 elements in many classically associated genes 
including but not limited to CYP24A1, CYP3A4, CYP3A, and ABCB1 (Thompson et 
al., 2002a).  Identifying the DR3 response element as a VDRE within these phase one 
genes further supports the hypothesis that the scope of VDR moves beyond that of 
bone remodeling and mineralization.  It also raises the question does the ability of 
VDR to regulate metabolic gene transcription extend beyond of phase one and three? 
Gene reporter testing 
The HEK-293 cell is an epithelial derived human embryonic kidney cell that was 
transformed using adenovirus DNA (Graham et al., 1977).  The kidney has long been 
known as a VDR target organ and HEK-293 have been well established with excellent 
transfection efficiency.  
The HepG2 cell is an immortalised liver cell line and has been used within this study 
as a comparison for expression as the liver remains the major site of metabolism 
associated with overall detoxification.  It is for these reasons that both these cell lines 
were used within this study.   
The gene reporter titrations were carried out in HEK-293 cells.  The cells were 
transiently transfected with the stated amounts and subsequently treated for 24 hours 
before the single glo luciferase assay was performed.  The preliminary titrations to 
establish the amount of nuclear receptor to transfect was ascertained to be 100ng 
before an overall decrease as witnessed on luciferase activity.  This could be due to an 
oversaturation of the promoter leading to a repressive effect on luciferase activity.  
The 2nd titration carried out was to establish the amount of promoter construct to 
transfect.  350ng (UGT1A1-290bp) and 500ng (UGT1A1-U2K) were deemed 
satisfactory before a loss of activity was witnessed.  The subsequent loss of activity 
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may have been due to an increase in promoter amount depleted the transfected nuclear 
receptor resulting in loss of activation; therefore all the subsequent luciferase assays 
used the above established amounts of transfectable material. 
The preliminary data also suggests that the presence of the nuclear reporter vectors is 
a pre requisite for transcriptional induction to occur, indicating the promoter to be 
nuclear receptor dependent in nature. 
The UGT1A1-290bp construct transfected with VDR/RXR and exposed to 10nM of 
1,25(OH)2D3 resulted in a 3.5 fold induction, compared to a negligible induction via 
PXR agonists in the HEK-293 cell line.  This result is interesting to note as it 
indicates a tissue specific response with regards the PXR related activation, even 
though both steroid nuclear receptors share approx. 90% homology with each other, 
PXR does not seem to boast any inductive capabilities of the UGT1A1 promoter 
enhancer module outside the hepatic environment.  This could be due to a lack of 
additional transcription factors such as HNF-1 alpha that is present in abundance 
within the liver, as it can be recruited to the promoter of a transcriptionally active 
gene as part of the pre initiation complex. 
Mammalian one Hybrid 
In conjunction with the luciferase assays we employed a mammalian one hybrid 
approach to assess the affinity each of the ligands have towards their respective 
receptors.  Within the experimental design we exposed VDR, FXR and RXR to 
various ligands including primary and secondary bile acids.  It is interesting to note 
that VDR was activated when exposed to 1,25(OH)2D3, lithocholic acid (LCA), and 
3-keto- lithocholic acid (3KLCA).  Each of the receptor plates were exposed to 
various ligands for 24 hours before analysis.  The VDR data is consistent with the 
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findings that 3KLCA and LCA show approx. the same affinity for VDR and therefore 
can produce a VDR mediated transcriptional response outside of the liver in a 
enterohepatic capacity, suggesting further an intestinal role in VDRs ability to 
regulate metabolic gene functionality (Makishima et al., 2002), (Jacobs et al., 2016).  
Both FXR and RXR reacted as expected, with FXR showing greatest affinity towards 
bile acid exposure, whereas RXR responded towards Bexarotene exposure.  
Bexarotene is an antineoplastic agent and is a third generation retinoid whose 
mechanism of action selectively activates the retinoid X receptor (RXR).  By 
selectively activating RXR the drug is able to induce cell differentiation and apoptotic 
pathways preventing drug resistance.  In addition to this the drug has anti angiogenic 
effects inhibiting cancer metastasis (Qu and Tang, 2010).        
 
UGT1A1-290bp DR3 K.O 
Once we has determined that VDR had the ability to induce UGT1A1 expression 
through the activation of the DNA binding motif located within the enhancer module, 
we proceeded to conduct site directed mutagenesis on the DR3 motif.  The 2-
nucleotide base changes (figure 4.10) resulted in a complete inability of VDR to bind 
the DR3 response element negating its ability to induce transcriptional activity.  It is 
interesting to note, that the PXR also lost its ability to bind the response element, 
indicating a shared site between both PXR and VDR.  This indeed does stand to 
reason that two steroid nuclear receptors would in essence have dual compatibility 
with DNA binding sites.  The loss of VDR activity within this region indicates that 
this is the only VDRE present within the enhancer module.  It must however be noted 
that the assays performed within this study incorporated only a small segment of the 
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overall gene promoter, and may not include all the VDRE response elements that 
regulate UGT1A1 transcriptional induction, however further mutagenesis needs to be 
performed within the 2K base pair vector as it is possible that potential VDRE 
elements could be present and missed otherwise.  However in the context of the 
enhancer module the presence and confirmatory identification of the VDRE has never 
been observed before making this an interesting observation, opening up the 
possibility of further exploitation outside of the hepatic environment with the 
potential for therapeutic application. 
EB1089 
EB1089 also known as Seocalcitol has been shown through this project that it has the 
ability to induce VDR driven gene activity to a higher degree than 1,25(OH)2D3.  This 
has also been noted in other researchers within the group, but a deeper investigation 
into why EB1089 has this ability has yet to be explored.  As EB1089 is an analogue 
of vitamin D it may not undergo the same metabolic degradation as the naturally 
occurring ligand, which is susceptible to metabolism through various phase one 
reactions chief among which remains CYP24A1.  This then may result in EB1089 
being able to elicit a response for a greater period of time resulting in a higher degree 
of promoter activation.  Another concept for consideration is the binding affinity 
EB1089 may have on target gene promoters?  Does EB1089 bind to response 
elements with greater affinity, at lower concentrations and still elicit highly 
responsive states of activation, witnessed at a transcriptional level?  It would be of 
great interest to study further the effects EB1089 has on VDR target genes and 











Chapter 4: Preliminary studies assessing the cross talk potential between nuclear 


















Nuclear receptors belong to a super family of proteins, and act as ligand activated 
transcription factors and are involved in a range of physiological processes.  The 
nuclear receptors respond to ligands such as steroids, hormones and retinoids.  This 
being said there is still a distinct group known as ‘orphan’ nuclear receptors that lack 
a defined endogenous ligand, therefore these receptors could in theory be regulated 
through other means such as post translation modification or SUMOlaytion (Chawla 
et al., 2001).   
The homology shared among nuclear receptor members’ stretches back through 
evolution.  This homology between receptors has allowed the sharing of ligands that 
activate each receptors activity.  This also leads to a potential cross talk between 
nuclear receptor members to ensure adequate and efficient physiological response i.e. 
metabolic turnover of harmful substrates.   
Due to the presence of the enhancer module within the UGT1A1 gene promoter, 
encompassing a number of nuclear receptors DNA binding motifs, we have 
hypothesized that a number of the receptors have an ability to interact and potentially 
affect the activation potential of UGT1A1.   
 Liver X Receptor (LXR) 
LXR is a cholesterol and bile acid sensor and has been termed the master regulator of 
hepatic metabolism (Huang et al., 2010).  Cholesterol is an essential part of all living 
beings, making up key elements within cellular membranes and is the precursor to all 
steroids and bile acids.  Cholesterol levels are however tightly controlled; as excessive 
amounts in the body has been linked with the development of cardiovascular disease 
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and atherosclerosis.  Transcriptional control of genes involved with cholesterol 
homeostasis is mediated in part by two nuclear receptors LXR and FXR.  Both these 
receptors like VDR form heterodimers with RXR, and work concurrently in 
controlling many key lipid and bile acid regulated genes.  LXR regulated genes are 
associated with the absorption, transportation, efflux and elimination of cholesterol, 
whereas FXR is bound by bile acids and acts as a bile acid sensor, controlling bile 
acid levels within the body.  Bile acids are the major end products of cholesterol in 
the liver, with FXR playing a major role in absorption and enterohepatic circulation 
events of many bile acids and cholesterol metabolites.     
Farenoid X Receptor (FXR) 
FXR has emerged as a key modulator of a number of metabolic processes within the 
liver related to cholesterol and bile acid metabolism and balance.  Much research has 
been carried out using synthetic FXR agonists to determine a selective subset of 
metabolic genes directly controlled through FXR activation.  Such findings suggest an 
interrelationship and crosstalk between bile acid metabolism, cholesterol metabolism, 
insulin resistance and triglyceride metabolism (Goodwin et al., 2000).  FXR having 
such a wide range of potential gene targets make it a possible target for therapeutic 
interventions, for a range of liver and bile acid disorders such as cholestasis or liver 






 Nuclear receptor crosstalk        
Cross talk is defined as the interaction between one or more transcription factors 
resulting in a cooperative induction or inhibition of gene transcription.  One of the 
major benefits of the crosstalk between transcription factors is that the gene specific 
responses are greatly increased in a cell type dependent manner.  Nuclear receptors 
have a direct effect on target genes however they can also have the potential to 
interfere with many signaling pathways, including; NF-κβ or AP-1. 
The cross talk between nuclear receptors such as LXR and FXR mean that cholesterol 
and bile acid levels within the body are tightly controlled and regulated.  UGT1A1 as 
a key metabolic gene involved in the metabolism of bilirubin, (break down product of 
haem), as well as other bile acids and exogenous substrates leads to the hypothesis of 
the potential cross talk between activating nuclear receptors, due to the close 
proximity each of the NR binding motifs have within the enhancer module.   
VDR has been shown to activate the UGT1A1 gene as effectively as other nuclear 
receptor activators and at far lower ligand concentrations.  This leads on to question; 
do the nuclear receptor members that have been shown to induce UGT1A1 work in 
concert and could they have the potential to generate a ‘super state’ of activation? 
In a recent study PXR was shown to have crosstalk potential with constitutive 
androstane receptor also known as CAR.  Evidence suggests that the cross talk is 
mediated through competition for common co activators or disruption of co 
activators.  In this instance PXR-CAR interference has been reported and a number of 
CYP450 enzymes, phase II metabolic genes including UGT1A1 and phase III 
transporters were shown to be down regulated after PXR activation (Pavek, 2016).   
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The presence of a number of nuclear receptor sites located within the 290bp range 
within the UGT1A1 genes shows the presence of and FXRE binding site in close 
proximity to the established PXRE/VDRE (figure 3.2 p127) both up stream and down 
stream.  With the FXRE sites being separate entities this suggests that there could be a 
synergistic or combinational effect witnessed when exposure to multiple agonists 
targeting separate nuclear receptor binding sites, which stands to reason throughout 
genetic evolution genes have developed a number of activation methods to maintain 
expression under a variety of stress condition.  Previously in this thesis PXR and 
VDR have been shown to competitively bind a single nuclear receptor-binding site.       
Therefore to what extent does the potential cross talk between nuclear receptors have 
on the activation of UGT1A1?  Will LXR and FXR have a synergistic effect with 
VDR to elicit a UGT1A1 transcriptional response? Finally does VDR activation of the 
UGT1A1 gene have an effect on the rate of glucuronidation?   
Within this chapter preliminary experiments were conducted to ascertain the potential 
impact VDR mediated activation may have on glucuronidation activity using the UGT 
Glo assay supplied by Promega. 
In addition to this combinational studies using luciferase technology was used to 
investigate if the addition of multiple ligands for a number of nuclear receptor targets 
included VDR, FXR and LXR agonists) have a cumulative effect on UGT1A1 
promoter activity.   
Finally real time analysis was carried out to assess the effects inflammatory driven 
pathways have on VDR mediated target gene expression.  TNF alpha was used as an 



























4.2.1 UGT-Glo glucuronidation assay 
The UGT Glo assay was conducted using the LS180, colon adenocarcinoma cell line 
model.  The cells were seeded at 8x105 cell/100mm dish, and allowed to incubate 
overnight at 37°C, 5% CO2 and 95% air.  The cells were washed with 1 x PBS and 
subsequently treated with vehicle control or VDR ligands at indicated concentrations.  
Cell pellet were harvested 24 hours later using ice cold PBS and subject to standard 
whole cell lysate preparation, before whole cell protein concentration was determined 
using BCA protein quantification.   
Each reaction consisted of 50μg of protein lysate, UGT-Glo buffer, 50μM UGT multi 
enzyme substrate and water to a total of 30μl.  To this either 10μl of PCR grade water 
(corresponding negative controls) or 16mM UDPGA (final conc. of 4mM) was added.  
The reactions were conducted in triplicate and incubated at 37°C for 90 minutes.  
Only those reactions with the addition of UDPGA are able to glucuronidate the multi 
enzyme substrate.  The plate was then removed from the incubator and 40μl of 
Luciferin Detection Reagent with the addition of D-Cysteine was added to all the 
wells and allowed to incubate at room temperature for 20 minutes, this allowed for the 







4.2.2 TNF alpha treatment of LS180 cells 
TNF alpha sourced from Gibco was reconstituted at 100μg/ml in sterile PBS 
containing 0.1% bovine serum albumin and subsequently sterile filtered through a 
0.2μm filter, and frozen at -20 degrees.  LS180 cells were seeded into 6 well plates as 
previously described and allowed to adhere to the plates overnight, following standard 
protocols.  Each ligand treatment containing TNF alpha received a final concentration 
of 10ng/ml of cytokine.  To this appropriate ligands were added or vehicle control.  
The plates were then allowed to incubate for 24 hours before standard RNA extraction 
















































































































Figure 4.1: Preliminary luciferase experimentation: HepG2 & HEK-293 were transfected 
with pGL3-290pb-UGT1A1 reporter vectors in combination with the indicated expression 
constructs for LXR/RXR empty vector combinations followed by treatment 24hrs with 
respective cognate receptor ligand or vehicle controls or combinations there of.  Data are 
represented as means (± SEM) of two independent experiments, with each data point 














Figure 4.2: Preliminary luciferase experimentation: HEK-293 were transfected with 
pGL3-290pb-UGT1A1 (A) or U2K (B) reporter vectors in combination with the indicated 
expression constructs for VDR/FXR/RXR or empty vector combinations followed by 
treatment 24hrs with respective cognate receptor ligand or vehicle controls or combinations 
there of.  Data are represented as means (± SEM) of two independent experiments, with each 
data point performed in triplicate (n=3). 
 159 
4.3.1 Combinational ligand analysis using UGT1A1 promoter plasmid constructs 
The preliminary luciferase studies were carried out to assess the potential cumulative 
nature of agonists on the activation and the UGT1A1 promoter using Promega Single 
Glo system.  Both HepG2 and HEK-293 cells were transfected with LXR/RXR 
plasmid constructs using calcium phosphate methodologies, followed by 24hr 
treatment with each respective ligand combination (LXR; T0901317 ((T.O), and RXR 
(Bex) agonists). 
It has not been noted before the presence of an LXRE within the 290bp enhancer 
module of the UGT1A1 gene.  Figure 4.1 shows a definite response to LXR agonist 
indicating the presence of a potential full or partial LXRE previously undocumented.     
As can be witnessed from figure 4.1 the presence of both the LXR and RXR plasmid 
constructs within the HepG2 have very little impact on the activity of the UGT1A1 
promoter.  This could be due to an overall lack of additional promoter elements that 
may be required for LXR activation to occur effectively.  It does seem to indicate 
from figure 4.1 when exogenous LXR RXR is absent the UGT1A-290bp vector 
produced a stronger luciferase signal in HepG2 cells.  Perhaps there is sufficient 
endogenous LXR and RXR present within the cells to bind the promoter vectors and 
thus with the addition of exogenous constructs results in a squelching scenario 
rendering any activity mute?  Indeed the reverse holds true in HEK-293.  To achieve 
luciferase activity nuclear receptor vectors need to be introduced into the system.  
This being said there does not seem to be a cumulative effect amongst the treatments 
Bex and T.O. in the HEK-293 model.  Perhaps again a liver derived model contains 
additional factors required for transcriptional responsiveness that are lacking in other 
extra hepatic models?  As can be seen from the nuclear receptor illustration (figure 
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3.2 page 127) there is a HNF-1 binding site located approx. 63bp up stream from the 
start codon.  Perhaps the presence of HNF is required for optimal transcriptional 
activation to occur in the hepatic environment?      
In figure 4.2, HEK-293 cells were co transfected with RXR and FXR to cells 
containing both the full 2000bp and 290bp UGT1A1 constructs there was very little 
difference between induction levels of the UGT1A1 gene promoter constructs 
indicating the active regions for receptor binding must be within a common region 
shared between both constructs i.e. the 290bp enhancer region.  
The combinational analysis between VDR and FXR agonists suggests no cumulative 
induction is present.  Indeed in HEK-293 cells when exposed to the FXR agonist GW 
are shown to have a greater affinity for induction within this experimental system 
























A1, A3, A4, A6 (Tukey, 2004) 
(Tukey, 2012) 
CAR/RXR Phenobarbital A1, A6 (Sugatani, 2001) 
(Sngatani, 2008) 
FXR/RXR Bile Acids, (LCA, 
CDCA) 
A1 (Barbier, 2006) 
PPAR/RXR Fibrates, Oxidised 
Fatty Acids 
A1, A3, A9 (Barbier, 2003) 
(Tukey, 2006) 
(Morris, 2009) 
LXR/RXR oxysterols A1 (possible), A3, A4 (Barbier, 2006) 
(Verreault,2006) 
RXR/RXR Bex A1  




A1, A3, A4, A6 (Tukey, 2003) 
(Togawa, 2008) 
    









Figure 4.3: Table summarizing members of the Nuclear Receptor superfamily with their 































Figure 4.4 Established VDR target genes showing the effects TNF-alpha has on 
mRNA expression: LS180 cells were treated with previously established 
concentration of test ligand before RNA extraction was carried out plus/minus TNF-
alpha treatment. Extracted RNA was reverse transcribed subjected to qRT-PCR 
analysis as per manufacturer’s protocol. Data are represented as means (± SEM) of 
two independent experiments.      
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4.3.2 The effects cytokine TNF-alpha has on mRNA expression on established 
VDR targets in the LS180 cell line model. 
TNF alpha is a cell signaling protein known as a cytokine, involved in systemic 
inflammation and is one of the cytokines involved in the acute phase response.  A 
deregulation or dysfunction of TNF alpha has been associated with various diseases 
including IBD, cancerous states and Alzheimer’s disease.  TNF alpha has the ability 
to bind cell surface receptors that result in the downstream activation of the pro 
inflammatory pathway NF-Kapp-Beta or NF-kB is a protein complex that regulates 
the transcription of DNA.  NF-kB plays a major role in regulating immune response 
and has been linked to cancer development and progression as well as inflammatory 
and autoimmune conditions.  By utilizing a cytokine such as TNF alpha in this 
experimental set it has the potential to mimic, albeit at a basic level cells that have 
undergone a stress-inducing event, allowing analysis of gene activation profiles 
through qRT-PCR analysis.  Figure 4.4 indicates that when the pro inflammatory 
cytokine TNF alpha is present it has a selective inhibitory effect on those genes 
regulated by the vitamin D receptor.  PXR activation through Rifampicin in the case 
of ABCB1 shows little change in the presence of TNF alpha, further hinting at the 
selective repression of VDR specific target genes. This inhibition is of great 
importance as it indicates that even acute responses that may potentially lead to the 
development of chronic inflammatory based conditions have a fundamental impact on 
the bodies ability to regulate key genes involved in a host of metabolic and 
homeostatic roles.   
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NK-kB transcription factor promoted immunity by controlling many genes involved 
in the inflammatory response.  Cell surface binding of cytokines such as TNF alpha 
and pathogen associated molecular patters (PAMPs) stimulate a signaling cascade 
leading to the expression of target genes that regulate cellular proliferation and 
immune response.  NF-kB was first characterized in cells present in the hematopoietic 
system however it has now come to light that NF-kB activation can occur through 
many cells types with significant importance in liver, adipose tissue and the central 
nervous system, all of which has links with the development of inflammatory 
associated metabolic diseases (Baker et al., 2011).  However reduced VDR expression 
has been linked with the development of colonic inflammation as a result of systemic 
activation of NK-kB and disease progression. Therefore perhaps a prophylactic 
approach to maintain VDR levels may have the ability to reduce the activation of 
down stream inflammatory pathways thus inhibit the progression of inflammation 
driven pathology (Wu et al., 2010).   Figure 4.3 summarizes the already established 
inducers of UGT1A target genes along with the nuclear receptor responsible for 
transcriptional activation.  VDR has been added as it has been now shown through the 
work detailed in this thesis to induce a transcription of a number of UGT1A members 
























Figure 4.5: Preliminary UGT Glucuronidation Glo Assay: LS180 cells were seeded at 
8x105 cell/100mm dish, and allowed to incubate overnight at 37°C, 5% CO2 and 95% air.  
The cells were washed with 1 x PBS and subsequently treated with vehicle control VDR or 
PXR ligands at indicated concentrations above.  Only those reactions with the addition of 
UDPGA are able to glucuronidate the multi enzyme substrate. 40μl of Luciferin Detection 
Reagent with the addition of D-Cysteine was added to all the wells and allowed to incubate at 
room temperature for 20 minutes, before a luciferase reading was taken.   
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4.3.3 Preliminary UGT-Glo assay identifying if VDR agonists affect 
glucuronidation activity compared to established inducer PXR.   
Being unsuccessful isolating detectable UGT protein in previous experimental set ups, 
the next logical step was to assess if VDR agonists increased the rate of 
glucuronidation activity using the UGT Glo system commercially available through 
Promega.   
The assay allows for the analysis of the rate of glucuronidation activity under 
different stimulation events.  However this study was only a preliminary analysis and 
very little can be gleamed from it, the assay suggests that when LS180 cells when 
exposed to VDR agonists such as 1,25(OH)2D3 or EB1089 that there is a trend 
indicating an increase in glucuronidation activity. 
The UGT-Glo Assay provides a luminescent method for measure UGT activity.  The 
assay is designed to measure UGT activity from a number of sources including 
microsomes containing recombinantly expressed enzyme or microsomal preparations 
derived from mammalian tissue.  The assay uses proluciferin substrates that are then 
modified by the UGT enzymes and then converted to luciferin derivatives using D-
Cysteine during the detection steps.  Without this conversion facilitated by the UGT 
enzyme activity the proluciferin substrate will not produce light when incubated with 
the luciferase chemical.  It is of importance to note that the proluciferin substrate has 
specificities towards a number of UGT1A and 2B members therefore would not be 
able to show the glucuronidation activity of one member alone.  Light output is 
inversely proportional to UGT enzymatic activity.  Unfortunately the assay 
development was in its infancy when performed.  The assay is designed to be used 
with microsomal preparations containing active UGT enzyme sources commercially 
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or prepared from mammalian tissue sources.  The assay performed within this 
experimental set up used whole cell lysates from LS180 cells, which I now feel the 
model used not produce adequate amounts of the active enzyme for analysis within 
the Glo system.  Furthermore attempting to maintain stability of the enzyme activity 
during the protein extraction phase may have led to destruction of enzymatic activity 
that may have been present.  The use of a gentler lysis method could have been 
considered in an attempt to maintain integrity.       
There is a direct correlation between the amount of light emitted from the assay and 
the rate of glucuronidation activity.  I.e. reduced light emitted equates to an increase 
in the rate of glucuronidation.  An alternative approach would be to isolate 
glucuronidation metabolites and visualize using mass spectrometry.   
However before any meaningful conclusions can be made, further work is required to 
ascertain the potential implications VDR agonists have on the rate of glucuronidation, 
this was however beyond the scope of this thesis.  Furthermore this assay would allow 
the study and extrapolation of the varying mutant constructs generated within the 
study on the rate of glucuronidation activity.  Sourcing microsomal preparation from 
mammalian tissue from murine sources could be the way to establish this assay within 
the laboratory and I feel is the next step in understanding the role VDR plays in UGT 














































UDP-glucuronosyltransferases (UGTs) belong to the Phase II drug metabolizing 
enzyme super family. UGTs mediate the transfer of glucuronic acid, from UDP 
glucuronic acid to predominantly hydrophobic states, therefore increasing the rate of 
their detoxification and excretion from the body. 
 
 Deficiency in the expression and/or activity of UGTs has been shown to result in 
genetic and acquired diseases such as Crigler-Najjar syndrome and jaundice (inability 
to bread down bilirubin).  
 
UGT genes show tissue-specific distribution patterns as indicated through real time 
analysis previously undertaken within the body of work. The underlying mechanisms 
for this tissue specificity are not fully understood. Emerging evidence further 
supported by this thesis have demonstrated that nuclear receptors (NR), such as 
pregnane X receptor (PXR), constitutive androstane receptor (CAR), Liver X 
Receptor (LXR), and Vitamin D Receptor (VDR) can regulate UGTs and this NR-
mediated regulation may contribute to the tissue-specific expression pattern of UGTs 
(Yang et al., 2017).  
 
In addition, UGTs have been shown to be subject to the regulation by aryl 
hydrocarbon receptor (AhR) and other tissue-specific transcription factors (Tukey, et 
al). Furthermore based on UGTs capacity to catalyse the glucuronidation of xeno and 
endobiotics UGTs play an important role in hormonal homeostasis, energy 
metabolism, bilirubin clearance, and xenobiotic detoxification (Strassburg et al., 
2002). Therefore this chapter helps in elucidating UGT regulation by nuclear 
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receptors highlighting a broader significance in understanding UGT's functioning that 
may have further implications in a number physiological and pathophysiological 
states. 
 
Inflammation is central for the progression of chronic liver disease as well as systemic 
inflammation and the promotion cancer progression and development (Park et al., 
2014).  
 
NRs can directly interact with classic pro-inflammatory transcription factors including 
nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1). In addition, NRs 
repress pro-inflammatory gene expression by interference with Toll-like receptor 
(TLR) signalling that regulates transcriptional pathways involved in the innate 
immune response.  However, inflammatory processes can affect RNA expression and 
posttranslational modification of nuclear receptors and their target genes.  Figure 4.4 
highlight the impact systemic inflammatory pathway activation has on vitamin D 
receptor (VDR) dependant target genes is indicated. 
 
LXRs inhibit genes involved in the innate immune response and simultaneously 
induce genes for lipid metabolism, therefore providing a bridge between lipid 
metabolism and systemic inflammation (Ito et al., 2015).   
 
A number of studies has been performed in the field of atherosclerosis, focusing on 
macrophage function and LXRs ability to act as a cholesterol sensors allowing the 
increased expression of genes associated with reverse cholesterol transport, 
cholesterol conversion to bile acids, and intestinal cholesterol absorption (Arrese and 
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Karpen, 2010). LXRs exert anti-inflammatory effects by attenuating bacterial or LPS-
induced expression of pro-inflammatory proteins through inhibition of NF-κB 
pathway activation.  Recent studies suggest that LXR agonists also reduce 
inflammatory processes in chronic inflammatory liver diseases.   
 
 Reduced expression of VDR is associated with inflammatory rooted 
pathophysiology.  Apart from its classical actions in the gut and bone, 1,25(OH)2D3 
possess potent anti-proliferative and immune-modulatory properties and is exerted 
through VDR.  The presence of VDR in various tissues not including the gut and 
bone, along with their ability to regulate cellular differentiation, and anti-
inflammatory action, has set the stage for therapeutic exploitation of VDR ligands for 
the treatment of a number of various inflammatory indications and cancers, and opens 
the potential prophylactic applications to ensure inflammatory based disorders are not 
able to manifest as readily.   
Since the UGT family of enzymes is tightly regulated through the activity of the 
nuclear receptor superfamily, anything that may have a detrimental impact on NRs 
ability to regulate efficiently will have a direct impact on genes that rely on NR 
activation.  Since UGTs have been shown to have a wide and varying impact 
throughout the body on many physiological process involved in xenobiotic 
metabolism the implication within disease development and progression is now 
widely accepted and supported therefore allowing the potential exploitation with 
regards UGTs regulation through NR activity may lend itself to maintaining basal 





































5.1 General Discussion 
Since the discovery of vitamin D as an essential component of healthy biological 
functioning, the physiological role of vitamin D goes far beyond that of its’ classical 
roles in bone strength, mineralization, and calcium homeostasis (Bergwitz and 
Juppner, 2010).  Within the last ten to fifteen years researchers understanding of 
vitamin D and its functionality within the body has evolved greatly to include roles 
within immune response, cellular differentiation, and extra hepatic metabolism 
(Aranow, 2011).  A keen area of research at the moment remains the idea that vitamin 
D provides a baseline genome wide protection aiding in the overall protection of 
DNA from external assaults through the maintenance and baseline expression of 
certain key metabolic genes (Carlberg, 2014). 
The hypothesis that VDR has the ability to regulate and maintain basal expression 
levels of key metabolic genes is bolstered through its evolutionary history.  VDR is 
ubiquitously expressed throughout most human tissues and therefore are responsive to 
1,25(OH)2D3 (Wang et al., 2012). 
VDR shares its main structural characteristics with other nuclear receptors i.e. a 
highly conserved DNA and ligand binding domain respectively (Mangelsdorf et al., 
1995).  The DNA binding domain of VDR along with its heterodimeric partner RXR 
(Sone et al., 1991) specifically contacts the hexameric consensus sequence within 
genomic DNA allowing for efficient binding to its target sites.  The major binding 
motif, as determined by the steric constraints of the dimerizing DNA binding domains 
of both VDR and RXR is a direct repeat of two hexameric nuclear receptor (NR) 
binding motifs separated by three nucleotides (DR3) (Shaffer and Gewirth, 2004).  
Within the ligand binding domain of VDR there is a network of approximately forty 
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amino acids that form a ligand binding pocket, in which 1,25(OH)2D3 and synthetic 
ligands bind with high affinity.  Ligand binding results in a conformational change of 
altering drastically VDR’s protein-protein interaction profile; changing from a 
repressor protein to an activator. 
To further cement the hypothesis that VDR plays an integral role in overall genome 
protection, as well as basal activation of key regulatory genes, VDR has been shown 
to interact with the chromatin and histone remodeling proteins.  Chromatin itself 
provides a repressive potential ultimately stopping transcription factors from 
interacting directly with DNA.  This is contrasted with regions of the epigenome that 
show highly dynamic changes through the binding of VDR.  These changes involve 
DNA methylation, posttranslational modifications, including acetylation and 
phosphorylation, allowing the activation of VDR target genes that are involved in key 
regulatory processes throughout the body.   
A number of ChIP-chip analyses have been carried out through the works of Pike et 
al, and have identified a wide range of VDR specific target genes through ChIP 
analysis on enhancer and regulatory regions within mouse promoters including but 
not limited to; Trpv6 (Meyer et al., 2006), CYP24A1 (Meyer et al., 2010), and Cbs, 
(Kriebitzsch et al., 2011).   
Vitamin D serum concentrations vary widely between one individual and the next.  
There are a number of factors that can affect this; 1) differences in diet 2) varying 
degrees of sunlight exposure, 3) age, and 4) genetic and epigenetic variations.  As a 
result of chronically low vitamin D status, accelerated age related conditions could 
result including bone loss, and increased risk of falls and fractures.   
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This poses an important question, whether an insight into the transcriptome and 
genomic actions of 1,25(OH)2D3 and by extension the vitamin D receptor can help in 
an individual’s overall basal genome protection, and therefore an individual’s 
responsiveness/need for vitamin D.  A study by (Carlberg et al., 2013) was carried out 
using a cohort of 71 individuals who participated in a five-month vitamin D 
intervention study.  They noted only a subset of individuals showed a significant 
correlation between genetic transcription events and serum 1,25(OH)2D3 
concentration, suggesting that at a molecular level not all the participants gained any 
benefit from the vitamin D supplementation.  This could be due to a number of 
factors; 1) they had reached their optimal vitamin D status before the trial began or 2) 
they possess a polymorphism making them less responsive to vitamin D.  Furthermore 
a negative correlation was noted between vitamin D status and the inflammatory 
marker interleukin 6 (IL-6), highlighting the potential role VDR may play in 
inflammatory response pathways.   
Research into further understanding the role VDR plays within the body is still 
ongoing.  Within this thesis we have identified that VDR has the ability to regulate 
the activity of members of the phase two metabolic gene family, UGT1A.   
The UGT1A family members are involved in glucuronidation reactions i.e. the 
transfer of glucuronic acid to metabolic substrates making the substrate more 
hydrophobic in nature.   
The UGT1A family of genes has been of great interest since the mid 1990’s and have 
been identified as the most important phase II metabolic gene members.  UGT’s have 
been shown to be regulated through many nuclear receptors including but not limited 
to PXR, CAR and FXR (Bock and Köhle, 2004).   
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This thesis has identified that the vitamin D receptor also has the ability to regulate a 
number of UGT1A members, focusing mainly on UGT1A1, due to this genes 
involvement in a number of hereditary disease states involved in bilirubin metabolism 
as well as its role in extra hepatic tissues.    
 The major tissue associated with phased metabolism has always been the liver.  
Hepatic tissues express a plethora of metabolic genes across all three phases of 
metabolism.  Liver tissue does express UGT1A family members however this thesis 
proposes that the extra hepatic expression of UGT1A1 is as of equal importance if not 
more important in biotransformation and detoxification vs. hepatic expression.  Tukey 
et al supports this observation. Through the development of K.O mouse models 
specifically knocking out the intestinal expression of UGT1A1 resulted in death of the 
animal subject, comparatively a knockout of the hepatic expression resulted in the 
intestinal expression compensating for the loss hepatic expression (Fujiwara et al., 
2012).   
One of the major observations through this study is that VDR can directly bind and 
regulate the transcriptional activity of UGT1A members as it identified in chapter one.  
The ability of VDR to actively regulate the transcriptional activity of this family of 
genes has not been documented before.  In addition to this VDR along with its 
heterodimeric partner RXR has been shown to directly bind DNA response elements 
and not require the use of tertiary protein interactions.  This observation was achieved 
through our cyclohexamide studies. 
This led us to question how effective is VDR compared to other nuclear hormone 
receptors in activating UGT1A members and UGT1A1 specifically? 
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To this end a comparative analysis was carried out to assess the transcriptional 
potential of VDR against known prototypical inducers of UGT1A1 activity.  PXR and 
FXR have been well established and inducers of a number of phased two metabolic 
genes including UGT1A1 (Kanno et al., 2016), (Fang et al., 2013).   
Through the study and identification of the enhancer module within the UGT1A1 
promoter it has allowed for the precise location of the potential DR3 response element 
employed through VDR/RXR binding to be identified and assessed.  Interestingly the 
DR3 motif has previously been identified by Tukey et al as a PXR binding site.  Due 
to the homology shared between many of the steroid hormone receptors it stands to 
reason that a number of the receptors have the potential to share binding motifs.  This 
evidently held true for this DR3 motif.  When the ability of VDR was disrupted 
through site directed mutagenesis this not only knocked out VDR’s ability to bind but 
PXR’s ability also (Chen et al., 2012).   
Furthermore, when considering the potency of the activation potential across the 
nuclear receptor activators it is interesting to note that the VDR based ligands, both 
natural and synthetic achieved transcriptional activation when exposing cell models to 
concentrations in the nano molar ranges compared to those in the micro molar ranges 
when we consider PXR and FXR agonists.  That variance in itself could bode well for 
potential therapeutic application.  
VDR also seems to achieve transcriptional responsiveness independent of other 
nuclear receptors.  When combining VDR and FXR agonists there was no synergistic 
response, supporting that both receptors employ different DNA response elements 
within the enhancer module.  Furthermore preliminary studies were conducted to 
assess if VDR activation of UGT1A members had an impact on the rate of 
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glucuronidation within a basic cell line model.  To achieve this a luciferase based 
approach was employed, and the preliminary assessment looked promising as VDR 
agonists had an overall impact on glucuronidation activity, however further work is 
essential to assess completely the statistical significance as it was beyond the scope of 
this project.         
It was also observed that VDR’s ability to regulate UGT1A activity was far more 
effective in extra hepatic environments.  HepG2 cells do not express adequate levels 
of VDR to achieve statistically significant transcriptional activity even when VDR 
was artificially transfected into the cells.  (This could be due in part due to the 
transfection efficiency of the HepG2 cell line).  Furthermore the transcriptional 
responses seen in the LS180 cell line model were far more transcriptionally 
responsive, and further supported by the overall basal expression of a number of 
UGT1A members compared across both HepG2 and LS180. Figure 5.1 details the 
proposed model of the potential role UGT1A members play in homeostatic genome 
protection.   The increase in basal expression within the intestine supports our theory 
that UGT1A1 could play a pivotal role in overall genome wide protection and 
detoxification within the body.  Our data shows the presences of a never before 
identified VDRE site advancing the complexity and overall activation profile of the 
UGT1A gene family.  VDR has now been shown to be expressed in varying tissues 
throughout the body, and the role of VDR beyond simply bone health has been an 
area of keen research for many years lends credence to the fact that genes controlled 
via liganded VDR have the potential to be exploited for areas beyond bone health and 
structure.  The liver has long since been described as the primary detoxification organ 
within the body, however the intestinal tract, including the small intestine and colon 
are constantly under external stresses from a range of sources i.e. reactive oxygen 
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species, xenobiotics, primary/secondary bile acids and chemotherapeutics (Fang et al., 
2013), and has been documented that it plays just as an important role in overall 
detoxification and the genetic profile witnessed in that gut are of pivotal importance 
to establish and maintain an active an functioning metabolism.  It has also been 
documented that UGT1A1 expression inhibits the downstream activation of the 
inflammatory pathway NF-kB, furthermore it has been witnessed that key metabolic 
genes in cancerous states are reduced including UGT1A1 and CYP3A4 (Ghosh et al., 
2012).  This opens up further potential therapeutic applications through the artificial 
raising of key metabolic gene expression levels in healthy tissue, increasing the 
overall rate of detoxification, enabling the more precise targeting and destruction of 
cancerous cells due to their reduced capacity to metabolize the chemotherapeutic.   
UGT1A1 has been documented to also stabilize the expression of the ‘gate keeper’ of 
the genome, p53 (Shukla and Gupta, 2010), as well as activate downstream pathways 
including Nrf2 enabling the removal of reactive oxygen species (Wu et al., 2011).     
Our understanding of how UGT1A genes are controlled and their role within the body 
both in a hepatic as well as extra hepatic is ever changing and requires further 
investigation, as there are many potentials for therapeutic manipulations that could be 















Figure 5.1: Proposed model of UGT1A1’s potential ability to provide baseline protection 
against harmful xeno and endobiotic assault through direct regulation through the vitamin D 
receptor in healthy intestinal tissue, through the activation of downstream response 
pathways, with an additional prospective for therapeutic targeting to reduce non-specific 
cytotoxicity within healthy tissue.        
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 Limitations 
There were a number of limitations noted within this study.  The major one I feel 
being a lack of translational responses through the use of western blot analysis.  A 
number of attempts were made to isolate microsomal fractions for western blot 
analysis however this was trickier than first expected, and attempts at isolating this 
fraction failed.  If isolated we would have been able to assess the UGT1A and 
UGT1A1 at a protein level, allowing us to determine if VDR activation was producing 
an up regulation in protein production.  The second limitation noted is the lack of 
glucuronidation activity assays.  Having this within the study again would enable 
further deductions to be made regarding VDR’s overall effectiveness to regulate 
UGT1A responsiveness to its agonists.   
 Future work 
- Assess using ChIP analysis physical VDR interaction with DNA response 
elements. 
- Further define and establish a fully function glucuronidation assay to assess 
the effectiveness of VDR agonists on the rate of glucuronidation in 
comparison the known agonists.   
- Employ Mass spectrometry to isolate glucuronide metabolites to further 
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